register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00259168 | [
{
"id_field": "org_study_id",
"id_value": [
"02-005/03"
]
}
] | https://clinicaltrials.gov/study/NCT00259168 | Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? | The purpose of this study is to determine whether attenuation/normalization of elevated blood sugar after meals ameliorates vessel wall (endothelial) function in individuals with insulin resistance. | Insulin Resistance and Postprandial Endothelial Function: Does Early Intervention Make a Difference? | [
{
"name": "Nateglinide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Insulin Resistance",
"Impaired Fasting Glucose"
] | [
"Bispebjerg Hospital"
] | [
"Bayer AG",
"Novartis AG"
] | [
[
{
"name": "那格列奈",
"lang": "CN"
},
{
"name": "Nateglinide",
"lang": "EN"
},
{
"name": "ナテグリニド",
"lang": "JP"
}
]
] | null |
NCT07508644 | [
{
"id_field": "org_study_id",
"id_value": [
"RSVVaccine_AECOPD"
]
}
] | https://clinicaltrials.gov/study/NCT07508644 | RSV Vaccination to Reduce Recurrent AECOPD | Objectives: To determine whether respiratory syncytial virus (RSV) vaccination reduces the rate of all-cause moderate-to-severe acute exacerbations of COPD (AECOPD) in high-risk patients, and to characterise RSV-specific infection and immune responses in this population.<br/>Hypothesis: RSV vaccination in COPD frequent... | Open-label, Multicenter Trial of RSV Vaccination to Reduce Moderate-to-severe Exacerbations in COPD Frequent Exacerbators: Clinical Effectiveness and RSV-specific Immune Responses | [
{
"description": "A single dose of RSV vaccination (Arexvy, GlaxoSmithKline) at the start of study",
"name": "RSV vaccination (Arexvy, GlaxoSmithKline)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Patients who will receive RSV vaccination and standard of care",
"design_group_title": "RSV group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_desc... | [
"COPD",
"RSV"
] | [
"The Chinese University of Hong Kong"
] | [
"The University of Hong Kong"
] | [
[
{
"name": "重组呼吸道合胞病毒疫苗（GSK）",
"lang": "CN"
},
{
"name": "Respiratory Syncytial Virus Vaccine (GSK)",
"lang": "EN"
},
{
"name": "組換えRSウイルスワクチン",
"lang": "JP"
}
]
] | null |
NCT04102449 | [
{
"id_field": "org_study_id",
"id_value": [
"AP-CL-PSA-PI-12856"
]
},
{
"id_field": "acronym",
"id_value": [
"PSA-ULTRA"
]
}
] | https://clinicaltrials.gov/study/NCT04102449 | Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast | The main purpose of this study is to validate the ultrasound scores PsASon22 and PsASon13 in patients with active psoriatic arthritis undergoing a treatment with Apremilast. | Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast | [
{
"description": "Single arm receiving Apremilast and ultrasound examinations",
"name": "Apremilast",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Single group:<br/>Apremilast will be prescribed according to the patient information leaflet, i.e.:<br/>Dosage form: Oral pill Dosage and Frequency: First 6 days titration phase, followed by 30mg twice daily (in case of kidney problems 30mg once daily in the morning). Treatment du... | [
"Psoriatic Arthritis"
] | [
"Medizinische Universität Graz"
] | [
"Medical University of Innsbruck",
"Celgene Corp.",
"Medical University of Vienna"
] | [
[
{
"name": "阿普米司特",
"lang": "CN"
},
{
"name": "Apremilast",
"lang": "EN"
},
{
"name": "アプレミラスト",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PSA-ULTRA"
}
] |
NCT00576472 | [
{
"id_field": "org_study_id",
"id_value": [
"MEMFX2"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01CA078957"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01CA081... | https://clinicaltrials.gov/study/NCT00576472 | Learning Impairments Among Survivors of Childhood Cancer | Children surviving some types of cancer have a higher risk of developing learning problems after cancer treatment than do children who have not had cancer or its treatment. Cancer treatment may cause problems with learning, attention, and memory. The purpose of this study is to identify brain changes that may underlie ... | Learning Impairments Among Survivors of Childhood Cancer | [
{
"description": "Please see detailed description for dosing information and study design.",
"name": "Methylphenidate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Please see detailed description for dosing information and study design.",
"interven... | [
"Acute Lymphoblastic Leukemia",
"Brain Tumors"
] | [
"St. Jude Children's Research Hospital, Inc."
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸哌甲酯",
"lang": "CN"
},
{
"name": "Methylphenidate Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT05294406 | [
{
"id_field": "org_study_id",
"id_value": [
"21-054"
]
},
{
"id_field": "acronym",
"id_value": [
"STOPMiP-2"
]
}
] | https://clinicaltrials.gov/study/NCT05294406 | Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia | Malaria in pregnancy is a major cause of maternal and neonatal death in Papua, Indonesia. A recent trial in Papua showed that monthly intermittent preventive treatment (IPTp) with the long-acting artemisinin-based combination dihydroartemisinin-piperaquine (DP) among pregnant women in the second and third trimester was... | Evaluation of a Pilot Implementation of Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine to Prevent Adverse Birth Outcomes in Papua, Indonesia | [
{
"description": "Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)",
"name": "Intermittent preventive treatment in pregnancy (IPTp... | [
{
"design_group_description": "Pregnant women attending routine antenatal care visits in their second and third trimester are given a monthly, presumptive treatment dose of dihydroartemisinin-piperaquine of three tablets daily for three days (9 tablets). The first dose is given by directly observed therapy (DOT... | [
"Malaria in Pregnancy"
] | [
"Liverpool School of Tropical Medicine"
] | [
"Indonesia Ministry of Health",
"Universitas Gadjah Mada"
] | [
[
{
"name": "双氢青蒿素/哌喹/伯氨喹/甲氧苄啶",
"lang": "CN"
},
{
"name": "Dihydroartemisinin/Piperaquine/Primaquine/Trimethoprim",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "802459e8885e2400e2a0a95d52ded223",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "STOPMiP-2"
}
] |
NCT03893747 | [
{
"id_field": "org_study_id",
"id_value": [
"JSVCT048-2"
]
}
] | https://clinicaltrials.gov/study/NCT03893747 | Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China | This study evaluates three batches consistency, immunity duration and safety of inactivated Enterovirus 71(EV-A71) vaccine(vero cell) post-marketing among children aged 6-35months in China.3000 subjects will be recruited in this study, of who 1500 subjects will be randomly assigned in a ratio of 1:1:1 to receive one of... | Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China | [
{
"description": "500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor",
"name": "The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"ty... | [
{
"design_group_description": "500 subjects will be randomly received the first batch vaccine producted by 40 L reactor",
"design_group_title": "the first batch vaccine producted by 40 L reactor",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5... | [
"Hand, Foot and Mouth Disease"
] | [
"Jiangsu Province Centers for Disease Control and Prevention"
] | [
"Wuhan Institute of Biological Products Co., Ltd."
] | [
[
{
"name": "肠道病毒71型灭活疫苗 (武汉生物制品研究所)",
"lang": "CN"
},
{
"name": "Enterovirus 71 vaccine(Wuhan Institute of Biological Products)",
"lang": "EN"
}
]
] | null |
NCT05823532 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00004430"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01MH131910-01"
]
}
] | https://clinicaltrials.gov/study/NCT05823532 | Anti-Inflammatory Challenge in Schizophrenia | This research project will explore negative symptoms of schizophrenia, such as motivational deficits, by examining the relationship between inflammation and reward-related brain regions. To accomplish this, we will administer a single infusion of either the anti-inflammatory medication infliximab or placebo (n=10 per g... | Targeting Inflammation-Induced Changes in Brain Reward Signaling and Motivational Deficits in Patients With Schizophrenia Using an Anti-Inflammatory Challenge. | [
{
"description": "Infliximab has FDA approval for the treatment of rheumatoid arthritis and inflammatory bowel syndrome. The current proposal represents the use of infliximab as an experimental tool to dissect the role of inflammatory processes leading to changes in brain reward circuitry and changes in specifi... | [
{
"design_group_description": "Subjects will be stratified by sex and randomized prior to this visit in preparation for the infusion. Vitals and safety labs will be drawn at this visit as well as urine testing for drugs of abuse and pregnancy testing for all biological females. Patients will receive breakfast f... | [
"Schizophrenia"
] | [
"Emory University"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "英夫利西单抗",
"lang": "CN"
},
{
"name": "Infliximab",
"lang": "EN"
},
{
"name": "インフリキシマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT02533934 | [
{
"id_field": "org_study_id",
"id_value": [
"12044"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1U01AI115714"
]
},
{
"id_field": "acronym",
"id_value": [
"STOP-CO"
]
}
] | https://clinicaltrials.gov/study/NCT02533934 | Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant | Retrospective/Prospective, open-label study using sofosbuvir based DAA therapy to treat HIV/HCV coinfected pre or post liver transplant participants | A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant | [
{
"description": "Treatment of Hepatitis C with sofosbuvir based HCC therapy",
"name": "Harvoni",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"SOF/LDV"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Prospective and retrospective treatment for HCV",
"design_group_title": "Treatment with Sofosbuvir based HCV Therapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"int... | [
"HIV",
"Hepatitis C",
"Cirrhosis"
] | [
"The University of California, San Francisco"
] | [
"National Institutes of Health Clinical Center",
"University of Maryland",
"Columbia University",
"Icahn School of Medicine at Mount Sinai",
"The Johns Hopkins University",
"National Institute of Allergy & Infectious Diseases",
"University of Pennsylvania",
"Georgetown University"
] | [
[
{
"name": "来迪派韦索磷布韦",
"lang": "CN"
},
{
"name": "Ledipasvir/Sofosbuvir",
"lang": "EN"
},
{
"name": "レジパスビル アセトン付加物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a525ea8a38eaea952a8a23ea02aa8a20",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "STOP-CO"
}
] |
NCT02089841 | [
{
"id_field": "org_study_id",
"id_value": [
"3.0.2011"
]
},
{
"id_field": "acronym",
"id_value": [
"ALE"
]
}
] | https://clinicaltrials.gov/study/NCT02089841 | Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. | Artemether-lumefantrine has been used in Tanzania as first-line treatment for uncomplicated malaria since 2007. Nonetheless, a report of increased proportion of patients with parasitaemia on day 1 following treatment with artemisinin based combination therapies has emerged from Kenya. Similarly, resistance against arte... | Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania. | [
{
"description": "Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.",
"name": "Artemether-lumefantrine",
"normalized_type": ... | [
{
"design_group_description": "In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to... | [
"Plasmodium Falciparum Malaria"
] | [
"Muhimbili University of Health & Allied Science Institute"
] | [
"Karolinska Institutet"
] | [
[
{
"name": "复方蒿甲醚",
"lang": "CN"
},
{
"name": "Artemether/Lumefantrine",
"lang": "EN"
},
{
"name": "アルテメテル/ルメファントリン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ALE"
}
] |
NCT00800553 | [
{
"id_field": "org_study_id",
"id_value": [
"CRT108999"
]
}
] | https://clinicaltrials.gov/study/NCT00800553 | fMRI-behavioral Study of Cholinergic Augmentation With Donepezil in Healthy Sleep Deprived Adults | The purpose of this study was to characterize how the anti-cholinesterase inhibitor (AChE-I) donepezil modulates brain regions involved in visual short-term memory, episodic memory and inhibitory efficiency following 24 hours of total sleep deprivation using fMRI as an additional marker for drug effect. | The Neural and Behavioral Correlates of How Donepezil Modulates Memory and Inhibitory Efficiency in the Context of 24 Hours of Sleep Deprivation | [
{
"description": "5mg o.m. p.o. for approx. 2 weeks",
"name": "donepezil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Aricept"
],
"type": "Drug"
},
{
"description": "5mg of placebo for approx. 2 weeks",
"name": "Placebo",
"normalized_type": ... | [
{
"design_group_description": "donepezil, 5 mg p.o. for approx 2 weeks",
"design_group_title": "donepezil",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "5mg o.m. p.o. for... | [
"Sleep Deprivation"
] | [
"Duke-NUS Graduate Medical School Singapore"
] | [
"GSK Plc"
] | [
[
{
"name": "盐酸多奈哌齐",
"lang": "CN"
},
{
"name": "Donepezil Hydrochloride",
"lang": "EN"
},
{
"name": "ドネペジル塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00301262 | [
{
"id_field": "org_study_id",
"id_value": [
"A1481238"
]
}
] | https://clinicaltrials.gov/study/NCT00301262 | Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied | Men's quality of life (QoL) is potentially affected by mild erectile dysfunction (ED) to the same extent as it is by moderate and severe ED. This study will provide controlled clinical data measuring efficacy, QoL parameters and satisfaction changes in men with mild ED treated with Viagra versus those treated with a pl... | A Multi-Center, Parallel Group, Flexible Dose Trial With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Assess The Impact Of Viagra On The Sexual Satisfaction Of Men With Mild Erectile Dysfunction | [
{
"name": "Viagra (Sildenafil citrate)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Impotence"
] | [
"Viatris, Inc."
] | [
"Pfizer Inc."
] | [
[
{
"name": "枸橼酸西地那非",
"lang": "CN"
},
{
"name": "Sildenaifl Citrate",
"lang": "EN"
},
{
"name": "シルデナフィルクエン酸塩",
"lang": "JP"
}
]
] | null |
NCT04585737 | [
{
"id_field": "org_study_id",
"id_value": [
"OIC 008"
]
},
{
"id_field": "acronym",
"id_value": [
"DYAD"
]
}
] | https://clinicaltrials.gov/study/NCT04585737 | Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF | Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine | Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine in Virologically-suppressed Adults Living With HIV on Bictegravir/Tenofovir Alafenamide/emtricitabine-the DYAD Study | [
{
"description": "Experimental",
"name": "Dolutegravir / Lamivudine Pill",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Dovato"
],
"type": "Drug"
},
{
"description": "Active comparator",
"name": "Bictegravir / Emtricitabine / Tenofovir Alafenamide... | [
{
"design_group_description": "Treatment Group 1 (n=148): FDC of DTG/3TC (50mg/300mg) administered orally, once daily (QD), without regard to food.",
"design_group_title": "Treatment group 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",... | [
"HIV I Infection"
] | [
"Orlando Immunology Center P A"
] | [
"ViiV Healthcare Ltd."
] | [
[
{
"name": "多替拉韦钠/拉米夫定",
"lang": "CN"
},
{
"name": "Dolutegravir Sodium/Lamivudine",
"lang": "EN"
},
{
"name": "ドルテグラビルナトリウム・ラミブジン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "25a3e2aa25245988e3d595da8a998525",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "DYAD"
}
] |
NCT02415569 | [
{
"id_field": "org_study_id",
"id_value": [
"2014SDU-QILU-G07"
]
}
] | https://clinicaltrials.gov/study/NCT02415569 | Tailored Bowel Preparation According to Bristol Stool Form Scale | The Bristol stool form scale ( BSFS) based tailored bowel cleansing regimen might be helpful to improve bowel cleansing quality before colonoscopy. | Tailored Bowel Preparation According to Bristol Stool Form Scale: a Prospective, Randomized, Controlled, Investigator-blinded, Multicenter Study | [
{
"description": "Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.",
"name": "Standard Bowel Prep (2L PEG-ELP)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Sub... | [
{
"design_group_description": "Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.",
"design_group_title": "group1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Bowel Cleansing Quality"
] | [
"Shandong University"
] | [
"Qianfoshan Hospital of Shandong Province"
] | [
[
{
"name": "比沙可啶",
"lang": "CN"
},
{
"name": "Bisacodyl",
"lang": "EN"
},
{
"name": "ビサコジル",
"lang": "JP"
}
]
] | null |
NCT00941785 | [
{
"id_field": "org_study_id",
"id_value": [
"EC5550"
]
}
] | https://clinicaltrials.gov/study/NCT00941785 | Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso | The aim of the study is to determine whether piperaquine plus dihydroartemisinin (DHA-PQ) is as effective, and better tolerated, than sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ), when used for seasonal Intermittent Preventive Treatment (IPT) to prevent malaria in children aged 3 to 59 months in Bobo-Dioulasso, B... | Randomized Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of Dihydroartemisinin-piperaquine for Seasonal IPT to Prevent Malaria in Children Under 5 Years | [
{
"description": "Three monthly administrations of Duocotexcin (DHA-PQ):<br/>dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days",
"name": "DHA-PQ",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Seasonal IPTc with Duocotexcin (Ho... | [
{
"design_group_description": "Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October.",
"design_group_title": "DHA-PQ",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interven... | [
"Malaria"
] | [
"London School of Hygiene & Tropical Medicine"
] | [
"Beijing Holley-Cotec Pharmaceuticals Co. Ltd."
] | [
[
{
"name": "双氢青蒿素哌喹",
"lang": "CN"
},
{
"name": "Piperaquine tetraphosphate/Artenimol",
"lang": "EN"
}
]
] | null |
NCT01790685 | [
{
"id_field": "org_study_id",
"id_value": [
"NA_00079951"
]
},
{
"id_field": "acronym",
"id_value": [
"ORVO"
]
}
] | https://clinicaltrials.gov/study/NCT01790685 | Ozurdex for Retinal Vein Occlusion Study (ORVO Study) | To measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of Ozurdex. | Ozurdex for Retinal Vein Occlusion Study (ORVO Study) | [
{
"name": "dexamethasone implant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ozurdex"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Central Retinal Vein Occlusion",
"design_group_title": "CRVO",
"design_group_type": "Other",
"intervention": [
{
"intervention_name": "dexamethasone implant",
"intervention_other_name": [
"Ozurdex"
],
"intervention_type":... | [
"Retinal Vein Occlusion"
] | [
"The Johns Hopkins University"
] | [
"Allergan UC"
] | [
[
{
"name": "地塞米松",
"lang": "CN"
},
{
"name": "Dexamethasone",
"lang": "EN"
},
{
"name": "デキサメタゾン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "3ea802aae8e22555d2ee28ee242a8ea0",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ORVO"
}
] |
NCT00204698 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB 11690"
]
}
] | https://clinicaltrials.gov/study/NCT00204698 | Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment | This study proposes to investigate prospectively, the presence of molecular markers for inflammation in laryngopharyngeal reflux (LPR) patients and to study the effect of a proton pump inhibitor (Aciphex) on these molecular markers.<br/>The investigators will be evaluating a group of patients before and after treatment... | Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment | [
{
"description": "20 mg of aciphex taken twice daily",
"name": "Aciphex",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "All subjects will be given active drug.",
"design_group_title": "1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "20 mg of aciphex tak... | [
"Laryngopharyngeal Reflux"
] | [
"University of Utah"
] | [
"Pricara"
] | [
[
{
"name": "雷贝拉唑钠",
"lang": "CN"
},
{
"name": "Rabeprazole Sodium",
"lang": "EN"
},
{
"name": "ラベプラゾールナトリウム",
"lang": "JP"
}
]
] | null |
NCT00114400 | [
{
"id_field": "org_study_id",
"id_value": [
"AG0024"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01AG017160"
]
}
] | https://clinicaltrials.gov/study/NCT00114400 | BVAIT: B-Vitamin Atherosclerosis Intervention Trial | The purpose of this study is to examine whether vitamin B supplementation will reduce the progression of early atherosclerosis in individuals over 40 years old and without clinical evidence of cardiovascular disease (CVD). | B-Vitamin Atherosclerosis Intervention Trial (BVAIT) | [
{
"name": "folic acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "vitamin B12",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name":... | null | [
"Atherosclerosis"
] | [
"National Institute on Aging"
] | [
"Leiner Health Products, Inc."
] | [
[
{
"name": "维生素B12",
"lang": "CN"
},
{
"name": "Cyanocobalamin",
"lang": "EN"
},
{
"name": "シアノコバラミン",
"lang": "JP"
}
],
[
{
"name": "叶酸",
"lang": "CN"
},
{
"name": "Folic Acid",
"lang": "EN"
}
],
[
{
... | null |
NCT04315298 | [
{
"id_field": "org_study_id",
"id_value": [
"6R88-COV-2040"
]
}
] | https://clinicaltrials.gov/study/NCT04315298 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | Phase 2:<br/>The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.<br/>Phase 3 Cohort 1:<br/>The primary objective of the study is to evaluate the clinical efficacy of sarilumab... | An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19 | [
{
"description": "Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.",
"name": "Sarilumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Kevzara®",
"REGN88",
"SAR153... | [
{
"design_group_description": "Phase 2",
"design_group_title": "Sarilumab 200mg IV (P2)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Single or multiple intravenous (IV)... | [
"COVID-19"
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
"Sanofi"
] | [
[
{
"name": "沙利鲁单抗",
"lang": "CN"
},
{
"name": "Sarilumab",
"lang": "EN"
},
{
"name": "サリルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT02065687 | [
{
"id_field": "org_study_id",
"id_value": [
"GOG-0286B"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2013-02284"
]
},
{
"id_field": "secondary_id",
"id_value... | https://clinicaltrials.gov/study/NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in chemotherapy, such as paclitaxel and carboplatin, wor... | A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer | [
{
"description": "Given IV",
"name": "Carboplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Blastocarb",
"CBDCA",
"Carboplat",
"Carboplatin Hexal",
"Carboplatino",
"Carboplatinum",
"Carbosin",
"Carbosol",
"Carbotec... | [
{
"design_group_description": "Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progress... | [
"Endometrial Adenocarcinoma",
"Endometrial Clear Cell Adenocarcinoma",
"Endometrial Serous Adenocarcinoma",
"Endometrial Undifferentiated Carcinoma",
"Recurrent Uterine Corpus Carcinoma",
"Stage III Uterine Corpus Cancer AJCC v7",
"Stage IIIA Uterine Corpus Cancer AJCC v7",
"Stage IIIB Uterine Corpus ... | [
"The Gynecologic Oncology Group"
] | [
"National Cancer Institute"
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "盐酸二甲双胍",
"lang": "CN"
},
{
"name": "Metformin Hydrochloride",
"lang": "EN"
},
{
... | null |
NCT04288232 | [
{
"id_field": "org_study_id",
"id_value": [
"17683"
]
}
] | https://clinicaltrials.gov/study/NCT04288232 | Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan | Phase IIIb, multicenter, open-label, prospective, interventional study to assess the potential benefit of Aflibercept treatment administered IVT at a dosage of 2 mg with five monthly loading doses and then treat and extend over 48 weeks, with the primary endpoint as BCVA assessed at Week 52. | A Multicenter, Open-label, Prospective, Interventional Study to Assess the Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan | [
{
"description": "Intravitreal aflibercept Injection 2.0mg/0.05 ml",
"name": "Aflibercept Injection [Eylea]",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Intravitreal injection of aflibercept 2.0mg/0.05 ml Aflibercept was administered with 5 monthly loadings followed by treat-and-extend with a 4-week interval increment/decrement with maxima cap at 12 weeks to visual/anatomic stability.",
"design_group_title": "Intravitreal afli... | [
"Center-involved Diabetic Macular Edema"
] | [
"Taipei Veterans General Hospital"
] | [
"National Taiwan University Hospital",
"Chang Gung Memorial Hospital"
] | [
[
{
"name": "阿柏西普",
"lang": "CN"
},
{
"name": "Aflibercept",
"lang": "EN"
},
{
"name": "アフリベルセプト（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT01391858 | [
{
"id_field": "org_study_id",
"id_value": [
"2004-0643"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT00631891",
"NCT02213445"
]
}
] | https://clinicaltrials.gov/study/NCT01391858 | Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica | This study will compare the effects of oral pregabalin with placebo on postoperative pain and morphine usage after mastectomy.<br/>Pregabalin is an anticonvulsant agent approved by the United States Food and Drug Administration (FDA) for the treatment of neuropathic pain associated with post-herpetic neuralgia and diab... | Effects of Oral Pregabalin Versus Placebo on Postoperative Pain and Morphine Consumption After Mastectomy | [
{
"description": "150mg of pregabalin/placebo",
"name": "lyrica",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"pregabalin"
],
"type": "Drug"
}
] | [
{
"design_group_description": "pregabalin (lyrica)",
"design_group_title": "pregabalin",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "150mg of pregabalin/placebo",
... | [
"Post-operative Pain"
] | [
"The University of Texas Southwestern Medical Center"
] | [
"Pfizer Inc."
] | [
[
{
"name": "普瑞巴林",
"lang": "CN"
},
{
"name": "Pregabalin",
"lang": "EN"
},
{
"name": "プレガバリン",
"lang": "JP"
}
]
] | null |
NCT00435370 | [
{
"id_field": "org_study_id",
"id_value": [
"U01MH079639"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"U01MH079639"
]
}
] | https://clinicaltrials.gov/study/NCT00435370 | Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia | This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia. | Tropisetron With Risperidone for Schizophrenia | [
{
"description": "10 mg/day",
"name": "Tropisetron",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Navoban"
],
"type": "Drug"
},
{
"description": "placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "... | [
{
"design_group_description": "Tropisetron (10mg/day) + risperidone(6mg/day)",
"design_group_title": "Tropisetron",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "10 mg/day... | [
"Smoking Cessation",
"Schizophrenia"
] | [
"Baylor College of Medicine"
] | [
"National Institute of Mental Health"
] | [
[
{
"name": "利培酮",
"lang": "CN"
},
{
"name": "Risperidone",
"lang": "EN"
},
{
"name": "リスペリドン",
"lang": "JP"
}
],
[
{
"name": "盐酸托烷司琼",
"lang": "CN"
},
{
"name": "Tropisetron hydrochloride",
"lang": "EN"
}
]
] | null |
NCT01802749 | [
{
"id_field": "org_study_id",
"id_value": [
"MITO-16 -MANGO-OV2b"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2012-004362-17"
]
},
{
"id_domain": "ENGOT",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id... | https://clinicaltrials.gov/study/NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.<br/>Recently reported data suggest that patients with colon cancer who receive bevacizumab in m... | Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line | [
{
"name": "Bevacizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Avastin"
],
"type": "Drug"
},
{
"name": "Paclitaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Carboplatin",
"normalized_t... | [
{
"design_group_description": "Combination chemotherapy with ONE of the following regimens:<br/>* PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC (area under curve) 5 on day 1 every 4 weeks;<br/>* GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days;... | [
"Recurrent Ovarian Cancer"
] | [
"National Cancer Institute"
] | [
"Istituto di Ricerche Farmacologiche Mario Negri"
] | [
[
{
"name": "盐酸多柔比星脂质体",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride liposomal",
"lang": "EN"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MITO16MANGO2b"
},
{
"identifier_source": [
{
"code": "038e382e32e55822a5559eee55980d4e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
... |
NCT02839330 | [
{
"id_field": "org_study_id",
"id_value": [
"V89_18"
]
}
] | https://clinicaltrials.gov/study/NCT02839330 | A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age | This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797 healthy adults receiving placebo. Subjects were randomized in a 3:1 ratio to receive either aH5... | A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age | [
{
"description": "Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).",
"name": "aH5N1c",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Placebo: Saline inj... | [
{
"design_group_description": "aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)",
"design_group_title": "Group A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Intram... | [
"Avian Influenza"
] | [
"Seqirus GmbH"
] | [
"Biomedical Advanced Research & Development Authority (Barda)"
] | [
[
{
"name": "Influenza A (H5N1) monovalent vaccine, adjuvanted(CSL Ltd.)",
"lang": "EN"
}
]
] | null |
NCT04661280 | [
{
"id_field": "org_study_id",
"id_value": [
"APHP201183"
]
},
{
"id_field": "acronym",
"id_value": [
"CHOLINE-2"
]
},
{
"id_field": "secondary_id",
"id_value": [
"APHP201183"
]
},
{
"id_field": "bridge_id",
"id_value": [
"CTIS2024-51503... | https://clinicaltrials.gov/study/NCT04661280 | Donepezil Versus Non-drug Treatment in Alzheimer's Disease. | Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation.<br/>The aim of this study is to... | Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multicentric, Randomized, Open Study : the CHOLINE-2 Study | [
{
"description": "Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.",
"name": "Donepezil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Aricept"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Non-drug treatment, cognitive remediation, cognitive stimulation",
"design_group_title": "Cognitive remediation",
"design_group_type": "No Intervention"
},
{
"design_group_description": "Non-drug treatment, cognitive remediation, cognitive stimulation + Donepezil",... | [
"Alzheimer Disease, Early Onset"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
"Association France Alzheimer"
] | [
[
{
"name": "盐酸多奈哌齐",
"lang": "CN"
},
{
"name": "Donepezil Hydrochloride",
"lang": "EN"
},
{
"name": "ドネペジル塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CHOLINE-2"
}
] |
NCT04453826 | [
{
"id_field": "org_study_id",
"id_value": [
"SYSUCC-MYC-2020-1103"
]
}
] | https://clinicaltrials.gov/study/NCT04453826 | Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma | Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of high risk patients with nasopharyngeal carcinoma compared with those tr... | A Multicenter Randomized Clinical Phase 3 Trial of Induction Chemotherapy Plus Concurrent Chemo-radiotherapy With or Without Camrelizumab for High Risk Nasopharyngeal Carcinoma | [
{
"description": "1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.<br/>2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected i... | [
{
"design_group_description": "3 cycles of gemcitabin and cisplatin induction chemotherapy plus concurrent chemo-radiotherapy with concurrent and adjuvant camrelizumab therapy.",
"design_group_title": "Camrelizumab plus chemo-radiotherapy arm",
"design_group_type": "Experimental",
"design_group_type... | [
"Nasopharyngeal Cancer",
"Chemotherapy",
"Radiotherapy",
"PD-1 Therapy"
] | [
"Sun Yat-Sen University"
] | [
"Affiliated Tumor Hospital of Guangzhou Medical University",
"Zhongshan People's Hospital",
"Yue Bei People's Hospital",
"the First Affiliated Hospital of Sun Yat-Sen University"
] | [
[
{
"name": "卡瑞利珠单抗",
"lang": "CN"
},
{
"name": "Camrelizumab",
"lang": "EN"
}
]
] | null |
NCT00002888 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000065210"
]
},
{
"id_field": "secondary_id",
"id_value": [
"E-1395"
]
},
{
"id_field": "secondary_id",
"id_value": [
"SWOG-E1395"
]
},
{
"id_field": "secondary_id",
"id_value": [
"E-1395... | https://clinicaltrials.gov/study/NCT00002888 | Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin plus fluorouracil are more effective than paclitaxel plus cisplatin in treating patients with advanced hea... | A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER | [
{
"name": "cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "fluorouracil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name":... | null | [
"Head and Neck Cancer"
] | [
"Eastern Cooperative Oncology Group"
] | [
"National Cancer Institute"
] | [
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル",
"lang": "JP"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラ... | null |
NCT05695027 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAU0211"
]
}
] | https://clinicaltrials.gov/study/NCT05695027 | Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study | The objective of this study is to determine if a combination of oral nicotinamide and pyruvate (N&P) can maintain eye health as compared to placebo while standard-of-care intraocular pressure-lowering glaucoma medications are used to treat glaucoma.<br/>A total of up to 188 participants will be enrolled and randomized ... | Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study | [
{
"description": "Nutritional supplements",
"name": "Dietary supplements - Nicotinamide and Pyruvate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"t... | [
{
"design_group_description": "The N&P group will receive nicotinamide and pyruvate for 87 weeks (20 months).",
"design_group_title": "Nicotinamide and Pyruvate",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{... | [
"Primary Open Angle Glaucoma"
] | [
"Columbia University"
] | [
"Stanford University"
] | [
[
{
"name": "烟酰胺",
"lang": "CN"
},
{
"name": "Nicotinamide",
"lang": "EN"
},
{
"name": "ニコチン酸アミド",
"lang": "JP"
}
]
] | null |
NCT02527343 | [
{
"id_field": "org_study_id",
"id_value": [
"ISIS 304801-CS17"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2015-000493-35"
]
}
] | https://clinicaltrials.gov/study/NCT02527343 | The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy | The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in a randomized treatment (RT) period in participants with familial partial lipodystrophy (FPL). Following the randomized treatment period, participants who did not enter the open-label extension (OLE) period went straig... | A Randomized, Double-Blind, Placebo-Controlled, With an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy | [
{
"description": "300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).",
"name": "volanesorsen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"IONIS-APOCIIIRx",
"ISIS 304801"
],
"type": "Drug"
},
{
"description": "Vo... | [
{
"design_group_description": "Randomized Period: Volanesorsen-matching placebo as SC, QW for Weeks 1-52. Participants who received volanesorsen-matching placebo in RT period and not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.<br/>OLE... | [
"Familial Partial Lipodystrophy"
] | [
"Akcea Therapeutics, Inc."
] | [
"Ionis Pharmaceuticals, Inc."
] | [
[
{
"name": "Volanesorsen",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "3ae2d3ee595e25deae5aae4a2905ed3d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8e892435d302985428d24a99e80425e8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BRO... |
NCT03070886 | [
{
"id_field": "org_study_id",
"id_value": [
"NRG-GU002"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2016-00963"
]
},
{
"id_field": "secondary_id",
"id_value... | https://clinicaltrials.gov/study/NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormo... | Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel | [
{
"description": "Given orally (PO)",
"name": "Bicalutamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Casodex",
"Cassotide",
"Cosudex",
"ICI 176,334",
"ICI 176334",
"Utamide"
],
"type": "Drug"
},
{
"description": "Gi... | [
{
"design_group_description": "Patients receive androgen deprivation therapy comprising leuprolide acetate, goserelin acetate, degarelix, bicalutamide, flutamide, or nilutamide for 6 months. Beginning 8 weeks after the start of androgen deprivation therapy, patients receive EBRT for 7.5 weeks.",
"design_gro... | [
"Stage I Prostate Adenocarcinoma AJCC v7",
"Stage II Prostate Adenocarcinoma AJCC v7",
"Stage III Prostate Adenocarcinoma AJCC v7"
] | [
"NRG Oncology"
] | [
"National Cancer Institute"
] | [
[
{
"name": "醋酸地加瑞克",
"lang": "CN"
},
{
"name": "Degarelix Acetate",
"lang": "EN"
},
{
"name": "デガレリクス酢酸塩",
"lang": "JP"
}
],
[
{
"name": "比卡鲁胺",
"lang": "CN"
},
{
"name": "Bicalutamide",
"lang": "EN"
},
{
... | null |
NCT04394143 | [
{
"id_field": "org_study_id",
"id_value": [
"2020-00315"
]
}
] | https://clinicaltrials.gov/study/NCT04394143 | Effect of AD128 to Treat Obstructive Sleep Apnea | This study evaluates the combination of two drugs (AD128), to treat obstructive sleep apnea (OSA) severity. After a baseline evaluation and during 7 days, half of the participants will randomly receive this drug combination (AD128) and the other will receive a placebo, i.e. a drug without pharmaceutical effect. Neither... | Effect of AD128 on Obstructive Sleep Apnea Severity: a Randomized, Placebo-controlled, Double-blind, Cross-over Study | [
{
"description": "Oral administration of two capsules before sleep for 7 days.",
"name": "AD128",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral administration of two capsules before sleep for 7 days.",
"name": "Mannitol",
"normalized_... | [
{
"design_group_description": "The study specific intervention includes per oral administration of two capsules of AD128, once daily, just before lights out, for 7 days.",
"design_group_title": "AD128",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22... | [
"Sleep Apnea, Obstructive"
] | [
"Centre Hospitalier Universitaire Vaudois"
] | [
"Apnimed, Inc."
] | [
[
{
"name": "AD-128",
"lang": "EN"
}
]
] | null |
NCT04655586 | [
{
"id_field": "org_study_id",
"id_value": [
"NAPc-201/301"
]
},
{
"id_field": "acronym",
"id_value": [
"ASPEN"
]
}
] | https://clinicaltrials.gov/study/NCT04655586 | Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 | Sequential randomized, multicenter, active comparator study to evaluate the hypothesis that rNAPc2 (AB201), a novel, potent and highly selective tissue factor inhibitor with anticoagulant, anti-inflammatory and potential antiviral properties, shortens time to recovery compared to heparin in hospitalized patients with C... | Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN-COVID-19) | [
{
"description": "two dose levels of rNAPc2",
"name": "rNAPc2",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"AB201",
"Recombinant Nematode Anticoagulant Protein c2"
],
"type": "Drug"
},
{
"description": "standard of care heparin per institution ... | [
{
"design_group_description": "loading dose of 7.5 μg/kg SC on Day 1 followed by 5 μg/kg SC on Days 3 and 5",
"design_group_title": "rNAPc2 Higher Dose",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Covid19"
] | [
"ARCA biopharma, Inc."
] | [
"Colorado Prevention Center"
] | [
[
{
"name": "rNAPc2",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "2a8a20582534ade952028824920dd8d4",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a548aa832ea39545eaa5a220a20d8424",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ASP... |
NCT06082167 | [
{
"id_field": "org_study_id",
"id_value": [
"XL092-305; KEYNOTE-G06"
]
},
{
"id_domain": "European Medicines Agency",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"EU CTR: 2023-506308-24-00"
]
},
{
"id_domain": "Merck Sharp & Dohme ... | https://clinicaltrials.gov/study/NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma ... | A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | [
{
"description": "Specified doses on specified days",
"name": "Zanzalintinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"XL092"
],
"type": "Drug"
},
{
"description": "Specified doses on specified days",
"name": "Zanzalintinib-matched Placebo",
... | [
{
"design_group_description": "Subjects with R/M HNSCC will receive zanzalintinib + pembrolizumab",
"design_group_title": "Zanzalintinib + Pembrolizumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Head and Neck Squamous Cell Carcinoma"
] | [
"Exelixis, Inc."
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "Zanzalintinib",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "STELLAR-305"
}
] |
NCT02262936 | [
{
"id_field": "org_study_id",
"id_value": [
"14-0188-A"
]
},
{
"id_domain": "Baycrest",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"14-56"
]
},
{
"id_domain": "Physician Services' Incorporated Foundation",
"id_field": "seconda... | https://clinicaltrials.gov/study/NCT02262936 | Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older | Nocturia, or voiding at night, is an extremely troublesome symptom which is highly prevalent in the elderly. Desmopressin is a treatment for nocturia but it can result in hyponatremia (low blood sodium), particularly in those aged 65 and older. Fesoterodine is used for the treatment of overactive bladder (OAB). Recent ... | A Randomized Double-blinded Trial Comparing DEsmopressin to FEsoterodine in the Treatment of Severe Nocturia in Women Aged 65 and olDer: The DEFEND Trial | [
{
"name": "Desmopressin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Fesoterodine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.",
"design_group_title": "Desmo... | [
"Nocturia"
] | [
"Mount Sinai Hospital (Canada)"
] | [
"Physicians' Services, Inc. Foundation",
"Baycrest"
] | [
[
{
"name": "醋酸去氨加压素",
"lang": "CN"
},
{
"name": "Desmopressin Acetate",
"lang": "EN"
},
{
"name": "デスモプレシン酢酸塩水和物",
"lang": "JP"
}
],
[
{
"name": "富马酸非索罗定",
"lang": "CN"
},
{
"name": "Fesoterodine Fumarate",
"lang": ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DEFEND"
}
] |
NCT00978315 | [
{
"id_field": "org_study_id",
"id_value": [
"2009-010083-42"
]
},
{
"id_field": "acronym",
"id_value": [
"ViDiAs"
]
}
] | https://clinicaltrials.gov/study/NCT00978315 | Trial of Vitamin D Supplementation in Asthma | The study null hypothesis is that vitamin D supplementation will not influence time to upper respiratory tract infection or time to severe asthma exacerbation in adult and adolescent patients with asthma. | Randomised, Multi-centre, Double-blind, Placebo-controlled Trial of Vitamin D Supplementation in Adult and Adolescent Patients With Asthma | [
{
"description": "Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year",
"name": "Cholecalciferol",
"normalized_type": "98bb1fc78f3d456a8b67c466ae710699",
"type": "Dietary Supplement"
},
{
"description": "Miglyol oil will be administere... | [
{
"design_group_description": "Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year",
"design_group_title": "Vigantol oil",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
... | [
"Asthma"
] | [
"Barts & The London NHS Trust"
] | [
"National Health Service"
] | [
[
{
"name": "维生素D3",
"lang": "CN"
},
{
"name": "Colecalciferol",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ViDiAs"
}
] |
NCT02720094 | [
{
"id_field": "org_study_id",
"id_value": [
"HPTN 083"
]
},
{
"id_domain": "DAIDS ES",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"20725"
]
},
{
"id_field": "secondary_id",
"id_value": [
"20725;HPTN 083"
]
},
... | https://clinicaltrials.gov/study/NCT02720094 | Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men | This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW). | A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine For Pre-Exposure Prophylaxis in HIV-Uninfected Men and Transgender Women Who Have Sex With Men | [
{
"description": "30 mg tablet",
"name": "Cabotegravir Oral Tablet",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Oral cabotegravir"
],
"type": "Drug"
},
{
"description": "300 mg/200 mg fixed-dose combination tablets",
"name": "TDF/FTC tablets",
... | [
{
"design_group_description": "In Step 1, participants will receive daily oral CAB and daily oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive CAB LA and daily oral TDF/FTC placebo to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.",
... | [
"HIV Infections"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"ViiV Healthcare Ltd.",
"Gilead Sciences, Inc."
] | [
[
{
"name": "卡替拉韦钠",
"lang": "CN"
},
{
"name": "Cabotegravir sodium",
"lang": "EN"
},
{
"name": "カボテグラビル",
"lang": "JP"
}
],
[
{
"name": "恩曲他滨替诺福韦",
"lang": "CN"
},
{
"name": "Emtricitabine/Tenofovir Disoproxil Fumarate",
... | [
{
"identifier_source": [
{
"code": "2d503a2dee098aa422aad8ae3e8288ad",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "a838edaaa5a2805aa23e5892335a2292",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT01140893 | [
{
"id_field": "org_study_id",
"id_value": [
"EudraCT N° 2009-016384-11"
]
},
{
"id_field": "acronym",
"id_value": [
"EXEPUMP"
]
}
] | https://clinicaltrials.gov/study/NCT01140893 | Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes | The purpose of this study is to determine whether exenatide is effective to improve glycemic control among type 2 diabetic patients treated by insulin pump therapy. | Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial. | [
{
"description": "Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.<br/>From V1, research drug will be titrated from ... | [
{
"design_group_description": "55 subjects",
"design_group_title": "exenatide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Research drug (exenatide or placebo), will be... | [
"Type 2 Diabetes"
] | [
"Caen University Hospital"
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "艾塞那肽",
"lang": "CN"
},
{
"name": "Exenatide",
"lang": "EN"
},
{
"name": "エキセナチド",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EXEPUMP"
}
] |
NCT03519646 | [
{
"id_field": "org_study_id",
"id_value": [
"201612250MIPB"
]
}
] | https://clinicaltrials.gov/study/NCT03519646 | Eliglustat on Gaucher Disease Type IIIB | Evaluation of the safety in the combination usage of Cerdelga and Cerezyme in type III Gaucher disease patients and the efficacy on soft tissue diseases. | Evaluation of the Safety in the Combination Usage of Cerdelga and Cerezyme in Type III Gaucher Disease Patients and the Efficacy on Soft Tissue Diseases. | [
{
"description": "1. This is a 3-year study and the enrollment time of this study is 24 months.<br/>2. The participants have to receive the investigational agent, Cerdelga<br/>3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, an... | [
{
"design_group_description": "Besides regular ERT, patients also need to take Eiglustat for 24 months.",
"design_group_title": "Experimental Case_Eiglustat",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Gaucher Disease, Type III"
] | [
"National Taiwan University Hospital"
] | [
"Sanofi"
] | [
[
{
"name": "依鲁司他",
"lang": "CN"
},
{
"name": "Eliglustat",
"lang": "EN"
},
{
"name": "エリグルスタット酒石酸塩",
"lang": "JP"
}
]
] | null |
NCT02255253 | [
{
"id_field": "org_study_id",
"id_value": [
"2013BAI05B02"
]
}
] | https://clinicaltrials.gov/study/NCT02255253 | Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population | In this research, the investigators aim to compare the antihypertensive efficacy and safety of monotherapy of routine dose angiotensin receptor antagonist telmisartan (ARB) and diuretic Hydrochlorothiazide (HCTZ) in high sodium intake patients with mild to moderate hypertension. The research will be conducted in the ru... | Efficacy of Telmisartan 40mg and Hydrochlorothiazide 25mg Monotherapy in High Sodium Intake Patients With Mild to Moderate Hypertension: a Multicenter Randomized Double-blinded Parallel Controlled Trial | [
{
"description": "capsule,40mg per day,2 months",
"name": "Telmisartan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"China Resources Double-crane Pharmaceutical Co., Ltd"
],
"type": "Drug"
},
{
"description": "tablet, 25mg per day, 2 months",
"na... | [
{
"design_group_description": "capsule,40mg per day,2 months",
"design_group_title": "Telmisartan",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "capsule,40mg per day,2 mo... | [
"Hypertension"
] | [
"The George Institute for Global Health"
] | [
"Peking University People's Hospital"
] | [
[
{
"name": "氢氯噻嗪",
"lang": "CN"
},
{
"name": "Hydrochlorothiazide",
"lang": "EN"
}
],
[
{
"name": "替米沙坦",
"lang": "CN"
},
{
"name": "Telmisartan",
"lang": "EN"
},
{
"name": "テルミサルタン",
"lang": "JP"
}
]
] | null |
NCT07093762 | [
{
"id_field": "org_study_id",
"id_value": [
"2025-059"
]
}
] | https://clinicaltrials.gov/study/NCT07093762 | Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC | SMARCA4 mutation is clinically known to be an independent poor prognostic factor. Both TCGA and the investigators institution's preliminary research indicate that the median overall survival (OS) of mutated patients is significantly shorter than that of wild-type patients (32 months vs. 157.7 months, respectively, P=0.... | Efficacy and Safety Analysis of First-Line ABCP Four-Drug Combination Therapy in Advanced SMARCA4-Mutated Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Prespecified Subgroup Clinical Trial | [
{
"description": "Atezolizumab: 1200 mg IV every 3 weeks; Bevacizumab: 15 mg/kg IV every 3 weeks; Carboplatin: AUC 5 IV every 3 weeks; Paclitaxel: 175 mg/m² IV every 3 weeks. Treatment cycles: After 4-6 cycles, continue Atezolizumab + Bevacizumab as maintenance therapy until disease progression or unacceptable ... | [
{
"design_group_description": "1. Patients pathologically confirmed as having NSCLC, with histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC) that is not amenable to curative-intent concurrent chemoradiotherapy, metastatic, or recurrent (Stage IV) non-squamous NSCLC, staged... | [
"Non Small Cell Lung Cancer"
] | [
"900th Hospital of Joint Logistics Support Force of PLA"
] | [
"900th Hospital of Joint Logistics Support Force of PLA"
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
}... | null |
NCT00476242 | [
{
"id_field": "org_study_id",
"id_value": [
"#5936R R01 DA015822-01"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA015822"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT00126711"
]
},
{
"id_f... | https://clinicaltrials.gov/study/NCT00476242 | Memantine as a Supplement to Naltrexone in Treating Heroin Dependence | Prospective participants will undergo a screening process at the clinic to determine eligibility. After screening, eligible patients will complete an 8-day inpatient detoxification, followed by a 12-week outpatient phase. Patients will be randomly assigned to one of two conditions (1) Naltrexone + Placebo; (2) Naltrexo... | Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence | [
{
"description": "intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)",
"name": "Vivitrol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"intramuscular injection of Vivitrol 380 mg"
],
"type": "Drug"
},
{
"description": "Mema... | [
{
"design_group_description": "intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)",
"design_group_title": "Memantine and Vivitrol",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"... | [
"Opioid Dependence",
"Heroin Dependence"
] | [
"The New York State Psychiatric Institute"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "盐酸美金刚",
"lang": "CN"
},
{
"name": "Memantine hydrochloride",
"lang": "EN"
},
{
"name": "メマンチン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "纳曲酮",
"lang": "CN"
},
{
"name": "Naltrexone",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8a5ee88a94942408242a4a2e5a2244a3",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "NAMHS"
}
] |
NCT01748097 | [
{
"id_field": "org_study_id",
"id_value": [
"IV BIC for IVONCOL"
]
},
{
"id_field": "acronym",
"id_value": [
"IVBICONCOL"
]
}
] | https://clinicaltrials.gov/study/NCT01748097 | Intravenous Bicarbonate To Verify The Correct Position of IV Catheters in Oncological Patients Oncological Patients Receiving Chemotherapy | The investigators use bicarbonate injected to an intravenous line and the changes in the exhaled end-tidal carbon dioxide to verify whether the IV line is in the vein or surrounding tissue | Phase III Study to Assess the Utility of a New Innovative Technique Using Intravenous Bicarbonate to Verify the Correct Position of Patients Scheduled for Intravenous Bicarbonate | [
{
"name": "sodium bicarbonate 4.2%",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "injecting 20cc 4.2% to a newly administered IV line",
"design_group_title": "IV bicarbonate 4.2% 20 cc",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name... | [
"Detection of the Correct Position of Intravenous Line"
] | [
"Sheba Medical Center"
] | [
"Netherlands Ministry of Health, Welfare & Sport"
] | [
[
{
"name": "碳酸氢钠",
"lang": "CN"
},
{
"name": "Sodium Bicarbonate",
"lang": "EN"
},
{
"name": "炭酸水素ナトリウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "IVBICONCOL"
}
] |
NCT00571727 | [
{
"id_field": "org_study_id",
"id_value": [
"Study 1419"
]
}
] | https://clinicaltrials.gov/study/NCT00571727 | Long-Term Treatment With rhIGF-1 in GHIS | The objective of this study was to evaluate the long-term safety and effectiveness of mecasermin (the study drug) in children with growth failure due to severe Primary insulin-like growth factor-1 deficiency (Primary IGFD). | A Study of Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS) | [
{
"description": "injections BID of rhIGF-1, mecasermin",
"name": "mecasermin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Increlex"
],
"type": "Drug"
}
] | [
{
"design_group_title": "mecasermin, injections BID of rhIGF-1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "injections BID of rhIGF-1, mecasermin",
"intervention_na... | [
"Growth Hormone Insensitivity Syndrome"
] | [
"Ipsen SA"
] | [
"University of Oklahoma"
] | [
[
{
"name": "美卡舍明生（Ipsen SA）",
"lang": "CN"
},
{
"name": "Mecasermin (Ipsen SA)",
"lang": "EN"
}
]
] | null |
NCT02506140 | [
{
"id_field": "org_study_id",
"id_value": [
"D151100002015001"
]
},
{
"id_domain": "National Natural Science Foundation of China",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"81322019"
]
},
{
"id_field": "acronym",
"... | https://clinicaltrials.gov/study/NCT02506140 | Platelet Reactivity in Acute Non-disabling Cerebrovascular Events | Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides faster, greater, and more consistent P2Y12 inhibition than Clopidogrel in patients with acute coronary syndrome, irrespective of the genetic varia... | A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke. | [
{
"description": "This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.",
"name": "T... | [
{
"design_group_description": "Drugs: Ticagrelor and Acetylsalicylic acid.",
"design_group_title": "Ticagrelor/ASA",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "This gro... | [
"Stroke",
"Ischemic Attack, Transient"
] | [
"Beijing Tiantan Hospital"
] | [
"Beijing Municipal Science & Technology Commission"
] | [
[
{
"name": "硫酸氢氯吡格雷",
"lang": "CN"
},
{
"name": "Clopidogrel Bisulfate",
"lang": "EN"
},
{
"name": "クロピドグレル硫酸塩",
"lang": "JP"
}
],
[
{
"name": "替格瑞洛",
"lang": "CN"
},
{
"name": "Ticagrelor",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "dea355085aad3e2882224e2a925225ae",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PRINCE"
}
] |
NCT05613608 | [
{
"id_field": "org_study_id",
"id_value": [
"22-1894"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01AA029606"
]
}
] | https://clinicaltrials.gov/study/NCT05613608 | Alcohol Use Disorder and Cannabidiol | This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the con... | Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies | [
{
"description": "The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.",
"name": "Cannabidiol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Dr... | [
{
"design_group_description": "210mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.",
"design_group_title": "Full-Spectrum Cannabidiol",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
... | [
"Alcohol Use Disorder"
] | [
"University of Colorado Denver"
] | [
"National Institute on Alcohol Abuse & Alcoholism"
] | [
[
{
"name": "大麻二酚",
"lang": "CN"
},
{
"name": "Cannabidiol",
"lang": "EN"
}
]
] | null |
NCT03579602 | [
{
"id_field": "org_study_id",
"id_value": [
"BB-006"
]
},
{
"id_domain": "Pacific Pediatric Neuro-Oncology Consortium",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"PNOC012"
]
}
] | https://clinicaltrials.gov/study/NCT03579602 | Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery | Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in ... | A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System | [
{
"description": "Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.",
"name": "tozuleristide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BLZ-100",
"Tumor Paint"
],
"single_... | [
{
"design_group_description": "Subjects randomized to Arm 1 (<br/>9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.",
"design_group_title": "Arm 1 (no tozuleristide)",
"design_group_type": "Active Compara... | [
"Pediatric Central Nervous System Tumor"
] | [
"Blaze Bioscience, Inc."
] | [
"The Pacific Pediatric Neuro-Oncology Consortium Foundation"
] | [
[
{
"name": "Tozuleristide",
"lang": "EN"
}
]
] | null |
NCT01902810 | [
{
"id_field": "org_study_id",
"id_value": [
"12-205"
]
}
] | https://clinicaltrials.gov/study/NCT01902810 | Protective Effects of Propranolol in Adults | This efficacy and safety trial will examine the effects and safety of propranolol administered to adult patients with severe burn injury. The investigators hypothesize that propranolol will provide significant benefit to adults following severe burn injury at doses that are safe and do not increase risk of adverse infe... | Protective Effects of Propranolol in Adults Following Major Burn Injury: A Safety and Efficacy Trial | [
{
"description": "Propranolol by mouth given daily throughout hospitalization",
"name": "Propranolol",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"inderol",
"metoprolol"
],
"type": "Drug"
},
{
"description": "Placebo by mouth given daily throug... | [
{
"design_group_description": "Propranolol by mouth given daily throughout hospitalization",
"design_group_title": "Propranolol",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_descr... | [
"Burn"
] | [
"University of Texas Medical Branch"
] | [
"American Burn Association"
] | [
[
{
"name": "盐酸普萘洛尔",
"lang": "CN"
},
{
"name": "Propranolol Hydrochloride",
"lang": "EN"
},
{
"name": "プロプラノロール塩酸塩",
"lang": "JP"
}
]
] | null |
NCT05170009 | [
{
"id_field": "org_study_id",
"id_value": [
"20-12023076"
]
}
] | https://clinicaltrials.gov/study/NCT05170009 | Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza | This is a randomized, double-blind, placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant patients. Although there are no data about this treatment option currently available, the invest... | Randomized Double-blind, Placebo-controlled Single Center Pilot Study to Evaluate the Efficacy and Safety of Baloxavir in Combination With Oseltamivir in Adult Allogeneic Bone Marrow Transplant Recipients With Influenza | [
{
"description": "Weight-adjusted Baloxavir Marboxil (40 mg for patients weighing <80 kg and 80 mg for those weighing ≥80 kg) at baseline, day 4, and day 7.",
"name": "Baloxavir Marboxil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Xofluza"
],
"type": "Drug... | [
{
"design_group_description": "Active Baloxavir Marboxil and standard of care Oseltamivir",
"design_group_title": "Active and standard of care",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"int... | [
"Influenza"
] | [
"Weill Medical College of Cornell University"
] | [
"Genentech, Inc."
] | [
[
{
"name": "磷酸奥司他韦",
"lang": "CN"
},
{
"name": "Oseltamivir Phosphate",
"lang": "EN"
},
{
"name": "オセルタミビルリン酸塩",
"lang": "JP"
}
],
[
{
"name": "玛巴洛沙韦",
"lang": "CN"
},
{
"name": "Baloxavir Marboxil",
"lang": "EN"
... | null |
NCT04655625 | [
{
"id_field": "org_study_id",
"id_value": [
"AG0302-COVID19-JN-02"
]
}
] | https://clinicaltrials.gov/study/NCT04655625 | Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19) | This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers. | A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults | [
{
"description": "2 mg of AG0302-COVID19 twice at 2-week intervals",
"name": "Group A (AG0302-COVID19)",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Placebo twice at 2-week intervals",
"name": "Group A (Placebo)",
"normalized_type"... | [
{
"design_group_title": "Group A (AG-0302-COVID19)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "2 mg of AG0302-COVID19 twice at 2-week intervals",
"intervention_nam... | [
"COVID-19"
] | [
"AnGes, Inc."
] | [
"Japan Agency for Medical Research & Development"
] | [
[
{
"name": "AG0302-COVID19",
"lang": "EN"
}
]
] | null |
NCT00778908 | [
{
"id_field": "org_study_id",
"id_value": [
"GUIKEGONG-0816004-40"
]
}
] | https://clinicaltrials.gov/study/NCT00778908 | Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma | Based on the radiobiological findings that accelerated tumor repopulation in nasopharyngeal carcinoma occurs in the late-course of radiation therapy, the investigators hypothesize that intensity-modulated radiation therapy(IMRT) with concomitant boost schedule by increasing daily dose starting at the fifth week after i... | Late-Course Accelerated Hyperfractionated IMRT Versus Conventionally Fractionated IMRT in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Clinical Trial | [
{
"description": "1. IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease<br/>2. IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boo... | [
{
"design_group_description": "Late-course accelerated hyperfractionated IMRT with concomitant cisplatin chemotherapy",
"design_group_title": "A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interv... | [
"Nasopharyngeal Carcinoma"
] | [
"Guangxi Medical University"
] | [
"The People's Hospital of Guangxi Zhuang Autonomous Region"
] | [
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラチン",
"lang": "JP"
}
]
] | null |
NCT01953510 | [
{
"id_field": "org_study_id",
"id_value": [
"09/19"
]
},
{
"id_domain": "NHMRC Project Grant",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"566792"
]
},
{
"id_domain": "GlaxoSmithKline Biologicals",
"id_field": "secon... | https://clinicaltrials.gov/study/NCT01953510 | Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam | Pneumococcus is a group of bacteria that can cause pneumonia, meningitis and other diseases. These bacteria normally live in the nose of humans and are spread from person to person by touching or sneezing. There are vaccines available to protect against infection with these bacteria, and pneumococcus is currently the l... | Evaluation of Different Infant Vaccination Schedules Incorporating Pneumococcal Vaccination | [
{
"description": "PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein",
"name": "PCV10",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"10-valent pneumococcal conjugate vaccine",
"Synflorix"
],
"typ... | [
{
"design_group_description": "PCV10 administered at 2, 3, 4 and 9 months of age",
"design_group_title": "A: 3+1 PCV10",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": ... | [
"Pneumococcal Vaccines"
] | [
"Murdoch Childrens Research Institute"
] | [
"Gates Foundation (United States)",
"Menzies School of Health Research",
"GSK Plc",
"National Health & Medical Research Council",
"Institut Pasteur"
] | [
[
{
"name": "Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)",
"lang": "EN"
}
],
[
{
"name": "13价肺炎球菌多糖结合疫苗 (辉瑞制药)",
"lang": "CN"
},
{
"name": "Pneumococcal polysaccharide conjugate vaccine",
"lang": "EN"
},
{
"name": "沈降１３... | null |
NCT00764699 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB08-00213"
]
}
] | https://clinicaltrials.gov/study/NCT00764699 | Effect of Increlex® on Children With Crohn Disease | Patients with Crohn disease often have poor weight gain and short stature, yet the etiology of the poor growth is not well defined. Studies in chronically ill patients who do not have Crohn disease have suggested that inflammation causes IGF-1 deficiency due to inadequate IGF-1 generation. Previous studies of GH use in... | Effect of Increlex® on Children With Crohn Disease | [
{
"description": "rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.",
"name": "rhIGF (Increlex)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "Treatment with rhIGF (Increlex)",
"design_group_title": "rhIGF",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "rhIGF will be administered as... | [
"Crohn Disease"
] | [
"Nationwide Children's Hospital"
] | [
"Tercica, Inc."
] | [
[
{
"name": "美卡舍明生（Ipsen SA）",
"lang": "CN"
},
{
"name": "Mecasermin (Ipsen SA)",
"lang": "EN"
}
]
] | null |
NCT01899820 | [
{
"id_field": "org_study_id",
"id_value": [
"KEMRI_CT_2013/0017"
]
},
{
"id_domain": "KEMRI Scientific Steering Committee",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"SSC 2276"
]
},
{
"id_field": "acronym",
"id_value": [
... | https://clinicaltrials.gov/study/NCT01899820 | Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya | Artemisinin-based combination therapies (ACTs) are recommended for use against uncomplicated malaria in areas of multi-drug resistant malaria. The Ministry of Health, Division of Malaria Control (DOMC) rolled out the use of artemether-lumefantrine as the first line treatment for uncomplicated malaria in 2006.The develo... | Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya | [
{
"description": "Artemether 20mg Lumefantrine 120mg",
"name": "Artemether lumefantrine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Coartem"
],
"type": "Drug"
},
{
"description": "Dihydroartemisinin 20mg Piperaquine 160mg",
"name": "Dihydroarte... | [
{
"design_group_description": "Tablets, 1-4 tablets (weight calculated dose), BD, at hr 0, 8, 24, 36, 48 and 60.",
"design_group_title": "Artemether lumefantrine",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
... | [
"Malaria"
] | [
"KEMRI-Wellcome Trust Research Programme"
] | [
"Kenya Medical Research Institute",
"The World Bank"
] | [
[
{
"name": "双氢青蒿素哌喹",
"lang": "CN"
},
{
"name": "Piperaquine tetraphosphate/Artenimol",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EAPHLNP"
}
] |
NCT05926258 | [
{
"id_field": "org_study_id",
"id_value": [
"CHL.3-01-2021-M"
]
}
] | https://clinicaltrials.gov/study/NCT05926258 | Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Population | The goal of this clinical trial is to assess the efficacy and safety of Chloroprocaine 3% eye gel compared to Oxybuprocaine 0,4% eye drops when used for inducing ocular surface anesthesia in pediatric patients.<br/>74 Participants (male and female, aged 0-17 yrs) will be 1:1 randomized for receiving either the test dru... | A Prospective, Observer-blind, Randomized Clinical Trial to Investigate and Compare the Clinical Efficacy of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia for Clinical Practice in Pediatric Population | [
{
"description": "ocular surface anesthesia",
"name": "Chloroprocaine 3% eye gel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Chemical Abstracts Service (CAS) nr 3858-89-7"
],
"type": "Drug"
},
{
"description": "ocular surface anesthesia",
"name... | [
{
"design_group_description": "The assigned investigational product (2 drops) will be instilled in both eyes of each subject. Administrations will be performed at the clinical centre by the Investigator or his/her deputy on study day 1. For each administration, the 2 drops will be instilled one at the time, at ... | [
"Local Anesthetic"
] | [
"Sintetica SA"
] | [
"Cross Research LLC"
] | [
[
{
"name": "盐酸氯普鲁卡因",
"lang": "CN"
},
{
"name": "Chloroprocaine Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT03090880 | [
{
"id_field": "org_study_id",
"id_value": [
"P150963"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2016-002546-23"
]
},
{
"id_domain": "15-059",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_... | https://clinicaltrials.gov/study/NCT03090880 | Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE) | Prospective randomized open multicenter trial with blinded adjudication of endpoints to assess the efficacy of six-month low-dose LMWH (Low Molecular Weight Heparin) for the prevention of symptomatic or incidental VTE in patients with stage IV lung cancer and elevated D-dimer. | Long-term Prophylaxis of Venous Thromboembolism With Low-molecular-weight Heparin in Patients With Metastatic Lung Cancer | [
{
"description": "Subcutaneous tinzaparin 4,500 IU once daily for six months.",
"name": "Tinzaparin Sodium",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "usual care,",
"design_group_title": "Control",
"design_group_type": "No Intervention"
},
{
"design_group_description": "tinzaparin sodium",
"design_group_title": "Experimental",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "70... | [
"Venous Thromboembolism",
"Lung Neoplasm"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
"National Cancer Institute"
] | [
[
{
"name": "亭扎肝素钠",
"lang": "CN"
},
{
"name": "Tinzaparin Sodium",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PROVE"
}
] |
NCT01949311 | [
{
"id_field": "org_study_id",
"id_value": [
"R668-AD-1225"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2013-001449-15"
]
}
] | https://clinicaltrials.gov/study/NCT01949311 | Open-label Study of Dupilumab in Patients With Atopic Dermatitis | The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD).<br/>The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters ass... | An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | [
{
"name": "Dupilumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"DUPIXENT®",
"REGN668",
"SAR231893"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Participants will receive repeat doses of dupilumab",
"design_group_title": "Dupilumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Dupilumab",
... | [
"Atopic Dermatitis"
] | [
"Regeneron Pharmaceuticals, Inc."
] | [
"Sanofi"
] | [
[
{
"name": "度普利尤单抗",
"lang": "CN"
},
{
"name": "Dupilumab",
"lang": "EN"
},
{
"name": "デュピルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "23853852e9e234eade544403e0dee492",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "5e2d5a2e25e35282e52e835e33584229",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT01842841 | [
{
"id_field": "org_study_id",
"id_value": [
"HGT-GCB-091"
]
}
] | https://clinicaltrials.gov/study/NCT01842841 | Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease | Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB) that leads to progressive accumulation of glucocerebroside within macrophages and subsequent tissue and organ damage; typically of the liver, spleen, bone marrow, and brain. Type 1 Gaucher disease affects an estimated 30,000 per... | A Multicenter, Open-label Extension Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease | [
{
"description": "15-60 U/kg, EOW",
"name": "velaglucerase alfa",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"VPRIV"
],
"type": "Drug"
}
] | [
{
"design_group_description": "15 to 60 U/kg, EOW via intravenous infusion",
"design_group_title": "velaglucerase alfa",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "15-6... | [
"Gaucher Disease"
] | [
"Shire Plc"
] | [
"Quintiles, Inc. (California)"
] | [
[
{
"name": "维拉苷酶α",
"lang": "CN"
},
{
"name": "Velaglucerase Alfa",
"lang": "EN"
},
{
"name": "ベラグルセラーゼ アルファ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04762459 | [
{
"id_field": "org_study_id",
"id_value": [
"YX-L-202105"
]
},
{
"id_field": "acronym",
"id_value": [
"APEX"
]
}
] | https://clinicaltrials.gov/study/NCT04762459 | Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection | This is a multicenter, randomized, open label, phase III study. | Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for EGFR Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection: A Multicenter, Randomized Controlled, Open-label Clinical Study | [
{
"description": "Almonertinib 110mg PO once daily",
"name": "Almonertinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "500 milligrams per square meter (mg/m²) Pemetrexed",
"name": "Pemetrexed",
"normalized_type": "3d1aa88261d64c0384137... | [
{
"design_group_description": "Drug: Almonertinib 110 mg A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: The patient continues to receive treatment until the disease progresses or reaches termination criteria. The overall treatment last for 3 years.",
"design_group_titl... | [
"Non-small Cell Lung Carcinoma"
] | [
null
] | [
"Genecast Biotechnology Co. Ltd.",
"Jiangsu Hansoh Pharmaceutical Group Co., Ltd."
] | [
[
{
"name": "培美曲塞二钾",
"lang": "CN"
},
{
"name": "Pemetrexed Dipotassium",
"lang": "EN"
}
],
[
{
"name": "甲磺酸阿美替尼",
"lang": "CN"
},
{
"name": "Almonertinib Mesilate",
"lang": "EN"
}
],
[
{
"name": "顺铂",
"lang": "C... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "APEX"
}
] |
NCT00252733 | [
{
"id_field": "org_study_id",
"id_value": [
"D2453C00045"
]
},
{
"id_field": "secondary_id",
"id_value": [
"DIRECT"
]
},
{
"id_field": "secondary_id",
"id_value": [
"SH-AHM-0045"
]
},
{
"id_field": "acronym",
"id_value": [
"DIRECT"
... | https://clinicaltrials.gov/study/NCT00252733 | Diabetic Retinopathy Candesartan Trials | The primary objective is to determine whether candesartan, compared to placebo reduces the incidence of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients without retinopathy.<br/>The secondary objective is to determine whether candesartan, compared to placebo, beneficially influences the r... | Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy. | [
{
"description": "32 mg once daily oral tablet given over 60 months",
"name": "candesartan cilexetil",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ATACAND"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Placebo",
"design_group_title": "1",
"design_group_type": "No Intervention"
},
{
"design_group_description": "candesartan cilexetil",
"design_group_title": "2",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f... | [
"Type 1 Diabetes"
] | [
"AstraZeneca PLC"
] | [
"Takeda Pharmaceutical Co., Ltd."
] | [
[
{
"name": "坎地沙坦酯",
"lang": "CN"
},
{
"name": "Candesartan Cilexetil",
"lang": "EN"
},
{
"name": "カンデサルタン シレキセチル",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "8a583ee8eade548a2e255a2e2550899a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "DIRECT"
}
] |
NCT04765059 | [
{
"id_field": "org_study_id",
"id_value": [
"D5162C00042"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2019-003969-18"
]
},
{
"id_field": "acronym",
"id_value": [
"COMPEL"
]
}
] | https://clinicaltrials.gov/study/NCT04765059 | A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) | The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment. | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progressed Extracranially Following First-Line Osimertinib Therapy (CO... | [
{
"description": "Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin",
"name": "Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
... | [
{
"design_group_description": "All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin ([AUC] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed mainte... | [
"Non-small Cell Lung Cancer"
] | [
"AstraZeneca PLC"
] | [
"PAREXEL International Corp."
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{
"name": "シスプラ... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2382ae4ae3552d89922ae84e42e8d5e3",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "d3a8e22202ea3ed802e320a3582a9839",
"s... |
NCT02498301 | [
{
"id_field": "org_study_id",
"id_value": [
"IDCRP-080"
]
}
] | https://clinicaltrials.gov/study/NCT02498301 | Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD | The purpose of this study is to develop evidence on the relative efficacy of 2 rifaximin chemoprophylaxis regimens for the prevention of Travelers' Diarrhea (TD) in a deployed setting. An additional purpose is to explore the effect of chemoprophylaxis on microbial flora and antimicrobial resistance, and obtain paramete... | A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Personnel | [
{
"description": "Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to",
"name": "Rifaximin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Xifaxan"
],
"type": "... | [
{
"design_group_description": "rifaximin, 550 mg, once daily, by mouth",
"design_group_title": "Rifaximin 550 mg once/day",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "R... | [
"Travelers' Diarrhea",
"Functional Bowel Disorders",
"Reactive Arthritis"
] | [
"The Henry M. Jackson Foundation"
] | [
"United Kingdom Ministry of Defence",
"Naval Medical Research Center"
] | [
[
{
"name": "利福昔明",
"lang": "CN"
},
{
"name": "Rifaximin",
"lang": "EN"
},
{
"name": "リファキシミン",
"lang": "JP"
}
]
] | null |
NCT00151138 | [
{
"id_field": "org_study_id",
"id_value": [
"HyperPetII"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01HL057529"
]
}
] | https://clinicaltrials.gov/study/NCT00151138 | Cognitive/Cerebrovascular Consequences of HTN Treatment | Randomized trial of two antihypertensive drugs of known efficacy to investigate whether one has more favorable effects on brain blood flow and cognitive function. | Cognitive and Cerebrovascular Sequelae of Hypertension | [
{
"name": "Atenolol (drug), Lisinopril (drug)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "multiple_drugs",
"type": "Drug"
}
] | null | [
"Hypertension"
] | [
"University of Pittsburgh"
] | [
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "赖诺普利",
"lang": "CN"
},
{
"name": "Lisinopril",
"lang": "EN"
},
{
"name": "リシノプリル水和物",
"lang": "JP"
}
],
[
{
"name": "阿替洛尔",
"lang": "CN"
},
{
"name": "Atendol",
"lang": "EN"
},
{
"name": "ア... | null |
NCT02882737 | [
{
"id_field": "org_study_id",
"id_value": [
"16016762"
]
}
] | https://clinicaltrials.gov/study/NCT02882737 | The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus | This project is part of several studies exploring situations, where glucagon potential has lesser glucose elevating effect. Exercise can be one of these situations as exercise may reduce liver glycogen depots.<br/>The investigators aims are:<br/>1. To compare the increase in plasma glucose after 200µg glucagon given ei... | The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus | [
{
"name": "Glucagon before exercise",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Glucagon after exercise",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Glucagon after resting",
"normalized_type": ... | [
{
"design_group_description": "120 minutes after breakfast; a single subcutaneous bolus of 200µg glucagon is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.<br/>Exercise: Immediately thereafter, the patient will bicycle for 45 ... | [
"Type 1 Diabetes Mellitus"
] | [
"Hvidovre University Hospital"
] | [
"Technical University of Denmark"
] | [
[
{
"name": "胰高血糖素",
"lang": "CN"
},
{
"name": "Glucagon",
"lang": "EN"
},
{
"name": "グルカゴン",
"lang": "JP"
}
]
] | null |
NCT00878371 | [
{
"id_field": "org_study_id",
"id_value": [
"Hall Morphine TAA-01"
]
}
] | https://clinicaltrials.gov/study/NCT00878371 | Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier | The purpose for this study is to determine if surgery (repair of descending thoracic aneurysm) causes a temporary decrease in the Blood Brain Barrier's ability to remove drugs from the brain back into the blood. The Blood Brain Barrier surrounds the brain and the spinal cord. This Blood Brain Barrier acts as a filter a... | Identification and Quantification of the Effects of a Surgery-induced Peripheral Inflammatory Response on Changes in Drug Efflux Transporter Function in the Brain | [
{
"description": "All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively",
"name": "morphine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively",
"design_group_title": "morphine",
"design_group_type": "Other",
"intervention": [
{
"intervention_descripti... | [
"Dissecting Aneurysm of the Thoracic Aorta"
] | [
"Nova Scotia Health Authority"
] | [
"Dalhousie University"
] | [
[
{
"name": "硫酸吗啡",
"lang": "CN"
},
{
"name": "Morphine Sulfate",
"lang": "EN"
},
{
"name": "モルヒネ硫酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT03364725 | [
{
"id_field": "org_study_id",
"id_value": [
"IIS # 11-507"
]
},
{
"id_field": "acronym",
"id_value": [
"ELIMINATEC"
]
}
] | https://clinicaltrials.gov/study/NCT03364725 | Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study | To demonstrate that colocation treatment of substance use disorder and Hepatitis C infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of Hepatitis C virus in study participants. | Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care | [
{
"description": "Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.",
"name": "Glecaprevir-pibrentasvir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients",
"design_group_title": "Open Label Treatment Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Hepatitis C",
"Addict Heroin"
] | [
"ID Care PA"
] | [
"AbbVie, Inc."
] | [
[
{
"name": "格卡瑞韦/哌仑他韦",
"lang": "CN"
},
{
"name": "Glecaprevir/Pibrentasvir",
"lang": "EN"
},
{
"name": "グレカプレビル水和物/ピブレンタスビル",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ELIMINATEC"
}
] |
NCT05575180 | [
{
"id_field": "org_study_id",
"id_value": [
"43720"
]
}
] | https://clinicaltrials.gov/study/NCT05575180 | Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance | A single-centered randomized doubled blinded placebo-controlled cross-over trial comparing two the effect of two carbonic anhydrase inhibitors on exercise performance in acute hypoxia. Participants will be young (under 40 years of age), healthy males and females who are regularly physically active. | Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance | [
{
"description": "Oral acetazolamide",
"name": "Acetazolamide 250Mg Tab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral Methazolamide",
"name": "Methazolamide Pill",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "... | [
{
"design_group_description": "Drug: Methazolamide Dose: 100 mg b.i.d Duration: 2 days prior to testing + 1 hr prior to testing start Form: Oral",
"design_group_title": "Methazolamide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"i... | [
"High Altitude Effects"
] | [
"The University of Waterloo"
] | [
"The Wilderness Society"
] | [
[
{
"name": "醋甲唑胺",
"lang": "CN"
},
{
"name": "Methazolamide",
"lang": "EN"
}
]
] | null |
NCT02802514 | [
{
"id_field": "org_study_id",
"id_value": [
"201840"
]
}
] | https://clinicaltrials.gov/study/NCT02802514 | A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects | The drug effects will be studied after a single dose of 50 milligram (mg) albiglutide and a single dose of 10 microgram exenatide, to gain insight into the central mechanisms of nausea associated with Glucagon-like peptide-1 receptor (GLP-1R) agonists. This study will explore the potential differences at the expected t... | An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers | [
{
"description": "It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.",
"name": "Albiglutide 50mg",
"normalized_type": "3d1aa8... | [
{
"design_group_description": "In session 1, eligible subject will undergo off-therapy MRI scan Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI. In session 2, subject will receive single dose each of albiglutide placebo on Day 1 (Wee... | [
"Diabetes Mellitus"
] | [
"GSK Plc"
] | [
"The General Hospital Corp."
] | [
[
{
"name": "阿必鲁肽",
"lang": "CN"
},
{
"name": "Albiglutide",
"lang": "EN"
}
]
] | null |
NCT02444234 | [
{
"id_field": "org_study_id",
"id_value": [
"HS-15-00182"
]
}
] | https://clinicaltrials.gov/study/NCT02444234 | Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis | The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis. | Steady-State Pharmacokinetics of Tedizolid in Plasma and Sputum of Patients With Cystic Fibrosis | [
{
"description": "Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.",
"name": "Tedizolid PO",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Participants will be ran... | [
{
"design_group_description": "Tedizolid phophate 200mg tablet",
"design_group_title": "Tedizolid PO",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Participants will be r... | [
"Cystic Fibrosis"
] | [
"University of Southern California"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "磷酸特地唑胺",
"lang": "CN"
},
{
"name": "Tedizolid Phosphate",
"lang": "EN"
},
{
"name": "テジゾリドリン酸エステル",
"lang": "JP"
}
]
] | null |
NCT01373684 | [
{
"id_field": "org_study_id",
"id_value": [
"HBV11-01"
]
},
{
"id_field": "acronym",
"id_value": [
"PAS"
]
}
] | https://clinicaltrials.gov/study/NCT01373684 | PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients | This study intends to investigate whether addition of PEG-IFN alfa-2a in HBeAg-negative chronic hepatitis B patients who are pretreated with nucleos(t)ide analogues enhances the degree of HBsAg decline. | Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS) | [
{
"description": "180 μg per week s.c. for a total duration of 48 weeks.",
"name": "Peginterferon alfa-2a",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Pegasys"
],
"type": "Drug"
},
{
"description": "All patients are all currently being treated with ... | [
{
"design_group_description": "All patients are all currently being treated with long-term NA treatment. PEG-IFN will be given in a dose of 180 μg per week s.c. for a total duration of 48 weeks starting at week 0.",
"design_group_title": "Peginterferon alfa-2a add on",
"design_group_type": "Experimental... | [
"Chronic Hepatitis B"
] | [
"Foundation for Liver Research"
] | [
"Hoffmann-La Roche, Inc."
] | [
[
{
"name": "聚乙二醇干扰素α-2a",
"lang": "CN"
},
{
"name": "Peginterferon alfa-2a",
"lang": "EN"
},
{
"name": "ペグインターフェロン アルファ‐2a（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PAS"
}
] |
NCT02124655 | [
{
"id_field": "org_study_id",
"id_value": [
"393/2012"
]
}
] | https://clinicaltrials.gov/study/NCT02124655 | Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth. | The accumulation and maturation of oral biofilm in the gingival margin is widely recognised to be the primary aetiological factor in the development of chronic gingivitis. Based on this association, the current treatment of gingivitis is focused on biofilm disruption, which will normally include mechanical processes, b... | Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth: a Randomised Clinical Trial. | [
{
"name": "Essential oils",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Listerine"
],
"type": "Drug"
},
{
"name": "0.2% chlorhexidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Oraldine Perio"
],
"type... | [
{
"design_group_description": "A) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).",
"design_group_title": "Essen... | [
"Oral Biofilm",
"Mouthwash",
"Periodontitis"
] | [
"University of Santiago de Compostela"
] | [
"Johnson & Johnson"
] | [
[
{
"name": "葡萄糖氯己定",
"lang": "CN"
},
{
"name": "Chlorhexidine gluconate",
"lang": "EN"
},
{
"name": "クロルヘキシジングルコン酸塩",
"lang": "JP"
}
],
[
{
"name": "水杨酸甲酯",
"lang": "CN"
},
{
"name": "Methyl Salicylate",
"lang": "EN... | null |
NCT00138294 | [
{
"id_field": "org_study_id",
"id_value": [
"BCM H-21853"
]
},
{
"id_domain": "MedImmune Inc",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"Flu-035-09"
]
},
{
"id_domain": "Baylor College of Medicine",
"id_field": "secondary_id... | https://clinicaltrials.gov/study/NCT00138294 | Control of Epidemic Influenza Through a School-based Influenza Vaccination Program | The main purpose of this study is to learn if influenza vaccines (live attenuated and inactivated influenza vaccines), when given to school-aged children 4 to 18 years of age, can stop or lessen the influenza (flu) outbreak in the community. Another purpose is to show that vaccination of these children will significant... | Phase 4, School-based, Open-labeled Research Trial for Control of Epidemic Influenza Through a School-based Influenza Vaccination Program in Central Texas. | [
{
"description": "Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy... | [
{
"design_group_description": "Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) with be offered live attenuated or inactivated influenza vaccines through a school-based research vaccination program.",
"design_group_title": "Intervention... | [
"Influenza"
] | [
"Baylor College of Medicine"
] | [
"Sanofi Pasteur SA",
"National Institute of Allergy & Infectious Diseases",
"Novartis AG"
] | [
[
{
"name": "四价流感病毒裂解疫苗(Sanofi)",
"lang": "CN"
},
{
"name": "Tetravalent influenza vaccine(Split, inactivated)(Sanofi)",
"lang": "EN"
}
],
[
{
"name": "Influenza vaccine live(MedImmune LLC)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "22e82aea9209502e352e9e5a8025e298",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "CEI"
}
] |
NCT02592486 | [
{
"id_field": "org_study_id",
"id_value": [
"15-041-160127"
]
}
] | https://clinicaltrials.gov/study/NCT02592486 | The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine | The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza vaccine and pneumococcal vaccine with that of separate administration. | A Randomized, Open-label, Parallel Design Study to Compare the Immunogenicity of Simultaneous Administration Versus Sequential Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine | [
{
"description": "Injections of pneumococcal vaccine and influenza vaccine simultaneously.",
"name": "Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Pneumovax NP® and Fluvic HA syringe®"
],
"... | [
{
"design_group_description": "The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Jap... | [
"Pneumococcal Pneumonia",
"Influenza"
] | [
"Kameda Medical Center"
] | [
"Merck Sharp & Dohme Corp.",
"Pharmaceutical Product Development LLC",
"Osaka University"
] | [
[
{
"name": "23价肺炎球菌多糖疫苗 (沃森生物)",
"lang": "CN"
},
{
"name": "Pneumococcal polysaccharide vaccine 23-valent (Walvax Biotechnology)",
"lang": "EN"
}
]
] | null |
NCT02531971 | [
{
"id_field": "org_study_id",
"id_value": [
"HP-00063835"
]
}
] | https://clinicaltrials.gov/study/NCT02531971 | Fentanyl Patch Pharmacokinetics in Healthy Adults | The study to be performed will utilize already FDA-approved marketed products in healthy adults for the purpose to generate data for establishing rate of drug delivery comparisons between RLD (reference listed drug) Duragesic ® TDDS (transdermal drug delivery system) and Generic Fentanyl TDDS in healthy adults and to e... | Absolute Bioavailability/ Pharmacokinetic and Residual Drug Analysis of Duragesic ® Transdermal System and Generic Fentanyl Transdermal System in Healthy Adults | [
{
"description": "100 micrograms (2 millilitres) via intravenous injection",
"name": "Intravenous fentanyl citrate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "TDDS dosage is 25 micrograms/hour (worn for 72 h)",
"name": "Duragesic®",
"n... | [
{
"design_group_description": "Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one... | [
"Peer Review, Research"
] | [
"University of Maryland Baltimore"
] | [
"US Food & Drug Administration"
] | [
[
{
"name": "枸橼酸芬太尼",
"lang": "CN"
},
{
"name": "Fentanyl Citrate",
"lang": "EN"
},
{
"name": "フェンタニルクエン酸塩",
"lang": "JP"
}
],
[
{
"name": "芬太尼",
"lang": "CN"
},
{
"name": "Fentanyl",
"lang": "EN"
},
{
... | null |
NCT00283504 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB# 05-08-EX-0247"
]
}
] | https://clinicaltrials.gov/study/NCT00283504 | A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy | The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe asthmatics who have ongoing persistent asthma symptoms despite on moderate to high doses of inha... | A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair) | [
{
"description": "Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.",
"name": "ANTI-IGE THERAPY (X... | [
{
"design_group_description": "One arm:active drug",
"design_group_title": "all patients received Xolair/active drug",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Xolair... | [
"ALLERGIC ASTHMA"
] | [
"Children's Hospital of the King's Daughters"
] | [
"Genentech, Inc.",
"Novartis AG"
] | [
[
{
"name": "奥马珠单抗",
"lang": "CN"
},
{
"name": "Omalizumab",
"lang": "EN"
},
{
"name": "オマリズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04074421 | [
{
"id_field": "org_study_id",
"id_value": [
"(2019) Study No. 413"
]
}
] | https://clinicaltrials.gov/study/NCT04074421 | Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D | We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life. High-throughput sequencing combined with real-time quantitative PCR will be used to comprehens... | Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With Diarrhoea-predominant Irritable Bowel syndrome-a Multicentre Controlled Study | [
{
"description": "A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.",
"name": "Rifaximin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.",
... | [
{
"design_group_description": "Repeating treatment of Rifaximin",
"design_group_title": "Rifaximin group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "A non-aminogl... | [
"IBS - Irritable Bowel Syndrome",
"Gut Microbiota"
] | [
"The Second Affiliated Hospital Zhejiang University"
] | [
"Lishui Central Hospital",
"Zhejiang Chinese Medical University",
"Shanghai Renji Hospital Management Co., Ltd.",
"Peking Union Medical College Hospital",
"Sir Run Run Shaw Hospital",
"The First Affiliated Hospital of Wenzhou Medical College"
] | [
[
{
"name": "利福昔明",
"lang": "CN"
},
{
"name": "Rifaximin",
"lang": "EN"
},
{
"name": "リファキシミン",
"lang": "JP"
}
]
] | null |
NCT06103721 | [
{
"id_field": "org_study_id",
"id_value": [
"No.F.3-1/2023(ERRB)/Chairman"
]
}
] | https://clinicaltrials.gov/study/NCT06103721 | Role of Nebulized Dexmedetomidine in Blunting the Effects of Direct Laryngoscopy and Endotracheal Tube on Heart Rate and Blood Pressure. | The goal of this interventional study is to check the effectiveness of nebulized Dexmedetomidine in preventing the rise in blood pressure and heart rate in patients undergoing General Anesthesia. The study will be conducted in patients presenting for elective surgery either healthy or having co-existing medical conditi... | Preoperative Dexmedetomidine Nebulization in Blunting Hemodynamic Stress Response to Laryngoscopy | [
{
"description": "Dexmedetomidine will be diluted in 20 ml of Normal Saline to produce a concentration of 20 mcg/ml. Then it will be taken from the dilution at a dose of 1.0 mcg/kg and that will be added in 2-3 ml of Normal Saline to make it a final volume of 10ml. The resultant mixture will be used to nebulize... | [
{
"design_group_description": "This will be the intervention group. Patients entering this group through computer generated random numbers will receive nebulization Dexmedetomidine in the pre-operative area under the supervision of consultant anesthetist.",
"design_group_title": "Group Dexmedetomidine",
... | [
"Hemodynamic Instability"
] | [
"Pakistan Institute of Medical Sciences"
] | [
"Pakistan Institute of Medical Sciences"
] | [
[
{
"name": "盐酸右美托咪定",
"lang": "CN"
},
{
"name": "Dexmedetomidine Hydrochloride",
"lang": "EN"
},
{
"name": "デクスメデトミジン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT07357597 | [
{
"id_field": "org_study_id",
"id_value": [
"D926UL00001"
]
},
{
"id_field": "acronym",
"id_value": [
"TROPION-SWISH"
]
},
{
"id_field": "secondary_id",
"id_value": [
"D926UL00001"
]
}
] | https://clinicaltrials.gov/study/NCT07357597 | An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. | This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer. | A Phase IV, Open-Label, Single-Arm Study of Prophylaxis for Datopotamab Deruxtecan-related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer (TROPION-SWISH) | [
{
"description": "Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.",
"name": "Dexamethasone mouthwash",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Commercially available Dato-DXd is p... | [
{
"design_group_description": "Participants will use dexamethasone 0.5 mg/5 mL alcohol-free mouthwash (10 mL, 4 times daily, swish for approximately 2 minutes, then spit out without swallowing).<br/>Participants will remain without food or drink for at least 30 minutes after use of dexamethasone",
"design_g... | [
"Stomatitis"
] | [
"AstraZeneca PLC"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "德达博妥单抗",
"lang": "CN"
},
{
"name": "Datopotamab Deruxtecan",
"lang": "EN"
},
{
"name": "ダトポタマブ デルクステカン（遺伝子組換え）（JAN）",
"lang": "JP"
}
],
[
{
"name": "地塞米松",
"lang": "CN"
},
{
"name": "Dexamethasone",
"lan... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TROPION-SWISH"
}
] |
NCT02575183 | [
{
"id_field": "org_study_id",
"id_value": [
"WI195422"
]
}
] | https://clinicaltrials.gov/study/NCT02575183 | Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation | The lack of proven waterpipe smoking cessation interventions makes it important to explore interventions proven effective for cigarette smoking cessation. The investigators hypothesize that Varenicline (Chantix) administrated for 12 weeks is associated with higher sustained quit rate at 12 weeks compared to placebo. Th... | Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation | [
{
"description": "A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators ... | [
{
"design_group_description": "76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive Varinecline with instructions for administration for 12 weeks starting 1 week before \"Smoking Quit Date\" as suggested by the manufacturer: Days 1 to 3: 0.5 ... | [
"Nicotine Dependence"
] | [
"American University of Beirut Medical Center"
] | [
"Pfizer Inc."
] | [
[
{
"name": "酒石酸伐尼克兰",
"lang": "CN"
},
{
"name": "Varenicline Tartrate",
"lang": "EN"
},
{
"name": "バレニクリン酒石酸塩",
"lang": "JP"
}
]
] | null |
NCT01939093 | [
{
"id_field": "org_study_id",
"id_value": [
"NRCT-53069"
]
},
{
"id_field": "acronym",
"id_value": [
"MAP"
]
}
] | https://clinicaltrials.gov/study/NCT01939093 | Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis | The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with MAP. | Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis | [
{
"description": "If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.",
"name": "Diazepam",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
... | [
{
"design_group_description": "Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.",
"design_group_title": "Quetiapine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b35... | [
"Methamphetamine-induced Psychosis"
] | [
"University of Chulalongkorn"
] | [
"National Research Council of Thailand"
] | [
[
{
"name": "地西泮",
"lang": "CN"
},
{
"name": "Diazepam",
"lang": "EN"
},
{
"name": "ジアゼパム",
"lang": "JP"
}
],
[
{
"name": "桂利嗪",
"lang": "CN"
},
{
"name": "Cinnarizine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MAP"
}
] |
NCT04957927 | [
{
"id_field": "org_study_id",
"id_value": [
"747/RC/KEMU"
]
}
] | https://clinicaltrials.gov/study/NCT04957927 | Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age | To determine the Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age. | Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age | [
{
"description": "Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age",
"name": "Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 ... | [
{
"design_group_description": "Intranasal Fluticasone Propionate 50mcg/actuation in each nostril 24 hourly",
"design_group_title": "Intranasal Fluticasone Propionate Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention"... | [
"Allergic Rhinitis"
] | [
"King Edward Medical University"
] | [
"King Edward Medical University"
] | [
[
{
"name": "孟鲁司特钠",
"lang": "CN"
},
{
"name": "Montelukast sodium",
"lang": "EN"
},
{
"name": "モンテルカストナトリウム",
"lang": "JP"
}
],
[
{
"name": "丙酸氟替卡松",
"lang": "CN"
},
{
"name": "Fluticasone Propionate",
"lang": "EN"
... | null |
NCT00543296 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00013641"
]
}
] | https://clinicaltrials.gov/study/NCT00543296 | Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment | The purpose of this study is to collect data on patients with severe uveitis that have required re-implantation of the sustained-release fluocinolone drug delivery device due to depletion of study drug in their previous implanted device. | Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment | [
{
"description": "0.59 mg Fluocinolone Acetonide implant",
"name": "0.59 mg Fluocinolone Acetonide implant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Retisert"
],
"type": "Drug"
}
] | [
{
"design_group_description": "0.59 mg Fluocinolone Acetonide implant",
"design_group_title": "0.59 mg Fluocinolone Acetonide implant",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_desc... | [
"Uveitis"
] | [
"Duke University"
] | [
"Bausch & Lomb, Inc."
] | [
[
{
"name": "氟轻松丙酮酯",
"lang": "CN"
},
{
"name": "Fluocinolone Acetonide",
"lang": "EN"
},
{
"name": "フルオシノロンアセトニド",
"lang": "JP"
}
]
] | null |
NCT01970241 | [
{
"id_field": "org_study_id",
"id_value": [
"MMRF-13-3658"
]
}
] | https://clinicaltrials.gov/study/NCT01970241 | Inpatient Diabetes on Corticosteroids | Despite a significant problem with out-of-control glucose levels in patients with diabetes receiving corticosteroids for a variety of illnesses, there are no published protocols addressing how to adequately treat corticosteroid-induced hyperglycemia. Investigators propose to test a protocol using scheduled dosing of NP... | Inpatient Diabetes on Corticosteroids | [
{
"description": "NPH given per study table based on steroid dose and patient weight in kg.",
"name": "NPH",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"NPH Lilly Insulin"
],
"type": "Drug"
},
{
"description": "Given at 2 units per 50 mg/dl over 200 ... | [
{
"design_group_description": "Receive NPH with each corticosteroid dose during the study duration (2-5 days).<br/>Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg",
"design_group_title": "... | [
"Diabetes Mellitus"
] | [
"Hennepin Healthcare Research Institute"
] | [
"Eli Lilly & Co."
] | [
[
{
"name": "精蛋白人胰岛素（诺和诺德）",
"lang": "CN"
},
{
"name": "Isophane Protamine Human Insulin(Novo Nordisk A/S)",
"lang": "EN"
}
]
] | null |
NCT02375724 | [
{
"id_field": "org_study_id",
"id_value": [
"D6560C00001"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-004715-37"
]
},
{
"id_domain": "Clinical Trial Protocol Code",
"id_field": "secondary_id",
"id_type": "Other Ident... | https://clinicaltrials.gov/study/NCT02375724 | BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH | The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg BID compared with placebo on COPD symptoms in a symptomatic patients population with moderate COPD and chronic bronchitis, and particularly assess the effects in cough by using specific tools to assess the occurrence and impact of this ... | A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL STUDY TO ASSESS THE BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH WHEN ADMINISTERED TO PATIENTS WITH COPD | [
{
"description": "Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler",
"name": "Aclidinium Bromide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler",
"name": "... | [
{
"design_group_description": "Aclidinium Bromide 400 μg twice daily by inhalation",
"design_group_title": "Aclidinium Bromide 400 μg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_desc... | [
"Pulmonary Disease, Chronic Obstructive"
] | [
"AstraZeneca PLC"
] | [
"A.Menarini Industrie Farmaceutiche Riunite Srl"
] | [
[
{
"name": "阿地溴铵",
"lang": "CN"
},
{
"name": "Aclidinium Bromide",
"lang": "EN"
},
{
"name": "アクリジニウム臭化物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "838525ea22885d8493228ed09285253d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "M-34273-46"
}
] |
NCT04974151 | [
{
"id_field": "org_study_id",
"id_value": [
"CSPPT2-TT_2020"
]
},
{
"id_field": "acronym",
"id_value": [
"CSPPT2-TT"
]
}
] | https://clinicaltrials.gov/study/NCT04974151 | China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype | This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype.<br/>The study participants will be randomized to one of the three treatment groups:<br/>Group A: amlodipine tablet (5mg), taken orally, once daily, serving as act... | Comparative Efficacy of Amlodipine Folic Acid vs. Amlodipine on the Risk of First Ischemic Stroke Among Participants With Hypertension and MTHFR 677 TT Genotype: A Multi-center, Randomized, Double-blind, Triple-dummy, Controlled Clinical Trial | [
{
"description": "The amlodipine used in this study is a listed product.",
"name": "Amlodipine besylate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Amlodipine"
],
"type": "Drug"
},
{
"description": "The amlodipine besylate and folic acid tablets ha... | [
{
"design_group_description": "Amlodipine 5mg x1 tablet + Amlodipine folic acid (dummy) x1 tablet + 5-MTHF (dummy) x2 tablets, taken orally, in the morning after waking up.<br/>Amlodipine tablets, amlodipine folic acid placebos, and 5-MTHF placebos are provided in aluminum-plastic blister plate. Each package in... | [
"Hypertension",
"MTHFR 677 TT Genotype"
] | [
"Shenzhen Ausa Pharmed Co. Ltd."
] | [
"The Affiliated Hospital of Guizhou Medical University",
"Weinan Central Hospital",
"Shenzhen Prospective Medical Technology Co., Ltd.",
"Yangjiang Peoples Hospital",
null,
"The First People's Hospital of Lianyungang",
"The Second Affiliated Hospital of Nanchang University",
"Peking University First H... | [
[
{
"name": "左甲柳叶酸钙",
"lang": "CN"
},
{
"name": "Levomefolate calcium",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CSPPT2-TT"
}
] |
NCT02417649 | [
{
"id_field": "org_study_id",
"id_value": [
"PIRRI/CT/001"
]
},
{
"id_field": "acronym",
"id_value": [
"AIACE"
]
}
] | https://clinicaltrials.gov/study/NCT02417649 | Advanced Immunological Approach in COPD Exacerbation | Chronic obstructive pulmonary disease (COPD) are characterized by frequent relapses, often resulting from common bacterial infections. Enhancing the immune response in these patients may decrease the frequency of these relapses. The use of a mechanic Polyvalent Bacterial Lysate (PMBL, Ismigen, 13 bacterial strains)may ... | Sublingual Administration of a Polyvalent Mechanical Bacterial Lysate in Patients With Moderate, Severe or Very Severe COPD According to GOLD Classification: a Multicenter, Double Blind, Randomized, Controlled, Phase IV Study | [
{
"description": "1. The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administra... | [
{
"design_group_description": "Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.",
"design_group_title": "Ismigen",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f2... | [
"Chronic Obstructive Pulmonary Disease (COPD)"
] | [
"Lallemand Pharma AG"
] | [
"Sprim Advanced Life Sciences SL"
] | [
[
{
"name": "Ismigen",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AIACE"
}
] |
NCT02041767 | [
{
"id_field": "org_study_id",
"id_value": [
"P090205"
]
},
{
"id_field": "acronym",
"id_value": [
"ERTAPRO"
]
}
] | https://clinicaltrials.gov/study/NCT02041767 | Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration | The purpose of this study is to demonstrate the prostatic diffusion in significant concentration of ertapenem achieved after a pre-operative single administration. | Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration | [
{
"description": "One single injection of 1g of ertapenem before surgery",
"name": "Ertapenem",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection",
"design_group_title": "group A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"int... | [
"Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
"Merck Sharp & Dohme Corp."
] | [
[
{
"name": "厄他培南钠",
"lang": "CN"
},
{
"name": "Ertapenem Sodium",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ERTAPRO"
}
] |
NCT00541814 | [
{
"id_field": "org_study_id",
"id_value": [
"RRK3367"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ISRCTN No. 60081949"
]
},
{
"id_field": "acronym",
"id_value": [
"CNIM-SRT"
]
}
] | https://clinicaltrials.gov/study/NCT00541814 | Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function | The purpose of this trial is to ascertain whether the withdrawal of calcineurin inhibitors (CNI) will lead to less kidney transplant damage when compared with minimisation. The investigators will assess this by comparing the degree of damage on kidney biopsies taken before and after minimisation/withdrawal of CNI. | Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial | [
{
"description": "Target drug level 50-100 ng/ml or cyclosporine withdrawal",
"name": "Cyclosporine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Neoral"
],
"type": "Drug"
}
] | [
{
"design_group_description": "CNI [Cyclosporine] minimisation Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to target blood level of 50-100 ng/ml.",
"design_group_title": "1",
"design_group_type": "Active Comparator",
"design_group_type_nor... | [
"Chronic Allograft Nephropathy"
] | [
"University Hospitals Birmingham Charity"
] | [
"Novartis AG"
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CNIM-SRT"
}
] |
NCT00453453 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00038961"
]
},
{
"id_domain": "Other",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"0009-2006"
]
},
{
"id_field": "acronym",
"id_value": [
"BOOST"
]
}
] | https://clinicaltrials.gov/study/NCT00453453 | BNP Therapy Observation Unit Outcomes STudy (BOOST) | The investigators hypothesize that patients admitted to an emergency department (ED) observation unit will have a decreased rate of hospital admissions and ED recidivism when treated with nesiritide versus standard therapy. The investigators also hypothesize that decreasing B-type Natriuretic Peptide (BNP) levels durin... | BNP Therapy Observation Unit Outcomes STudy | [
{
"description": "Nesiritide given orally in the emergency department",
"name": "Nesiritide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Natrecor"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Subjects who come into the ED with CHF will be treated with nesiritide",
"design_group_title": "Nesiritide",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_... | [
"Congestive Heart Failure"
] | [
"Emory University"
] | [
"Scios, Inc."
] | [
[
{
"name": "奈西立肽",
"lang": "CN"
},
{
"name": "Nesiritide Recombinant",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BOOST"
}
] |
NCT01188811 | [
{
"id_field": "org_study_id",
"id_value": [
"B7493-W"
]
}
] | https://clinicaltrials.gov/study/NCT01188811 | Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) | The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis. | Lipoic Acid for Neuroprotection in Secondary Progressive MS | [
{
"description": "1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.",
"name": "lipoic acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"alpha lipoic acid"
],
"type": "Drug"
},
{
"descrip... | [
{
"design_group_description": "28 subjects receive oral lipoic acid 1200mg daily",
"design_group_title": "Arm 1: lipoic acid",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description":... | [
"Multiple Sclerosis, Chronic Progressive"
] | [
"VA Office of Research and Development"
] | [
"Oregon Health & Science University"
] | [
[
{
"name": "硫辛酸",
"lang": "CN"
},
{
"name": "Lipoic acid",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "2052322daa82e88e2a295e05558e5524",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "2599aee828a0e52e9a250d2d84008ed4",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Lip... |
NCT00089843 | [
{
"id_field": "org_study_id",
"id_value": [
"5 R01 DK052625 (completed)"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DK052625"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value... | https://clinicaltrials.gov/study/NCT00089843 | Bone Loss in Women With Anorexia Nervosa | Women with Anorexia Nervosa have been found to have low bone density. The study will determine whether administration of low doses of a natural hormone, testosterone and/or risedronate, a medication to help prevent bone breakdown will improve or prevent bone loss in this condition. | IGF-1 and Bone Loss in Women Anorexia Nervosa | [
{
"description": "Testosterone patch 150mcg daily",
"name": "Testosterone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Intrinsa"
],
"type": "Drug"
},
{
"description": "Actonel (risedronate) 35mg PO one time weekly",
"name": "Actonel (risedronate... | [
{
"design_group_description": "Placebo Actonel (risedronate) and active testosterone patch",
"design_group_title": "2",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "... | [
"Anorexia Nervosa"
] | [
"The General Hospital Corp."
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases",
"National Center for Research Resources"
] | [
[
{
"name": "睾酮",
"lang": "CN"
},
{
"name": "Testosterone",
"lang": "EN"
}
]
] | null |
NCT02735031 | [
{
"id_field": "org_study_id",
"id_value": [
"ESR-15-10862"
]
}
] | https://clinicaltrials.gov/study/NCT02735031 | Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes | Approximately 25% of patients with type 1 diabetes have lost the capacity to timely detect hypoglycaemia, a condition referred to as impaired hypoglycaemic awareness (IHA) that causes a six-fold higher risk of severe, potentially hazardous, hypoglycaemia. IHA is usually the end-result of a process of habituation to rec... | Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Hypoglycaemic Awareness in Type 1 Diabetes | [
{
"description": "6 weeks treatment with exenatide on top of insulin treatment",
"name": "Exenatide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Byetta"
],
"type": "Drug"
},
{
"description": "6 weeks treatment with placebo on top of insulin treatmen... | [
{
"design_group_description": "Exenatide<br/>* week 1-2: 5 µg twice daily<br/>* week 3-6: 10 µg twice daily (if tolerated)",
"design_group_title": "EXENATIDE",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
... | [
"Diabetes Mellitus, Type 1",
"Hypoglycemia"
] | [
"Radboud University Medical Center"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "艾塞那肽",
"lang": "CN"
},
{
"name": "Exenatide",
"lang": "EN"
},
{
"name": "エキセナチド",
"lang": "JP"
}
]
] | null |
NCT02819141 | [
{
"id_field": "org_study_id",
"id_value": [
"16-000417"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R01HL130881"
]
}
] | https://clinicaltrials.gov/study/NCT02819141 | Self-management of Sedative Therapy by Ventilated Patients | The purpose of this randomized clinical trial is to test the efficacy of dexmedetomidine for the self-management of sedative therapy (SMST) in a sample of critically ill patients receiving mechanical ventilator support. The investigators hypothesis is that self-management of sedative therapy by mechanically ventilated ... | Efficacy of Self-management of Sedative Therapy by Ventilated ICU Patients | [
{
"description": "Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.",
"name": "Dexmedetomidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"P... | [
{
"design_group_description": "These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team",
"design_group_title": "Control",
"design_group_type": "No Intervention"
},
{
"design_group_description": "These patients will receive a basal intraven... | [
"Critical Illness",
"Anxiety",
"Respiratory Failure"
] | [
"Mayo Clinic"
] | [
"University of Minnesota",
"National Heart, Lung & Blood Institute"
] | [
[
{
"name": "盐酸右美托咪定",
"lang": "CN"
},
{
"name": "Dexmedetomidine Hydrochloride",
"lang": "EN"
},
{
"name": "デクスメデトミジン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT01064999 | [
{
"id_field": "org_study_id",
"id_value": [
"FDRT-002"
]
}
] | https://clinicaltrials.gov/study/NCT01064999 | A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer | Neoadjuvant chemoradiotherapy (CRT) has been the standard therapy for local advanced rectal cancer. Pathological complete response (pCR) is an important prognostic factor for local control and survival. A high intensity CRT increases not only the pCR rate, but also toxicity, especially diarrhea. Compared with tradition... | An Open Label, Randomized, Multi-center, Phase II/III Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy With Intensity-modified Radiation Therapy (IMRT) in Local Advanced Rectal Cancer | [
{
"description": "CRT:50mg/m2,IV,weekly*5 cycle CT: 130mg/m2,IV,d1,q 21 day",
"name": "Oxaliplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks",
"name": "Capecitabine",
"nor... | [
{
"design_group_description": "(RT 55Gy + CapOx) + a cycle of Xelox + Surgery",
"design_group_title": "High intensity group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": ... | [
"Rectal Cancer"
] | [
"Fudan University"
] | [
"Shanghai Renji Hospital Management Co., Ltd.",
"Zhejiang No. 1 Hospital",
"Zhejiang Cancer Hospital"
] | [
[
{
"name": "奥沙利铂",
"lang": "CN"
},
{
"name": "Oxaliplatin",
"lang": "EN"
},
{
"name": "オキサリプラチン",
"lang": "JP"
}
],
[
{
"name": "卡培他滨",
"lang": "CN"
},
{
"name": "Capecitabine",
"lang": "EN"
},
{
"name... | null |
NCT04920838 | [
{
"id_field": "org_study_id",
"id_value": [
"ANRS COV33 COVERAGE-Africa"
]
},
{
"id_field": "acronym",
"id_value": [
"COVERAGE-A"
]
}
] | https://clinicaltrials.gov/study/NCT04920838 | Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection | Coverage Africa is a nested study in the large Anticov platform trial that aims to generate data on new early treatment strategies for mild/moderate COVID-19 patients in resource-limited-settings to reduce the number progressing to severe forms requiring hospitalization, thereby relieving the burden on health care syst... | Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa) | [
{
"description": "Inhaled Ciclésonide: 320 mcg BID per day and Oral Nitazoxanide:2000 mg tablets daily (divided into two daily intakes of two tablets of nitazoxanide 500 mg) during 14 days.",
"name": "Nitazoxanide and Ciclésonide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug... | [
{
"design_group_description": "Patients in this arm will receive paracetamol during 14 days",
"design_group_title": "Paracetamol",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_desc... | [
"Covid19",
"Covid19 Drug Treatment",
"Severe Acute Respiratory Syndrome Coronavirus 2",
"SARS-CoV2 Infection"
] | [
"France Recherche Nord & Sud SIDA HIV-Hepatites"
] | [
"Barcelona Institute for Global Health",
"Institut National de la Santé et de la Recherche Médicale",
"The Alliance for International Medical Action Asso",
"Université de Bordeaux"
] | [
[
{
"name": "硝唑尼特",
"lang": "CN"
},
{
"name": "Nitazoxanide",
"lang": "EN"
}
],
[
{
"name": "布地奈德",
"lang": "CN"
},
{
"name": "Budesonide",
"lang": "EN"
},
{
"name": "ブデソニド",
"lang": "JP"
}
],
[
{
"... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "COVERAGE-A"
}
] |
NCT06115499 | [
{
"id_field": "org_study_id",
"id_value": [
"A022106"
]
},
{
"id_domain": "NCI Clinical Trial Reporting Program",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2023-06547"
]
},
{
"id_field": "secondary_id",
"id_value": [
... | https://clinicaltrials.gov/study/NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) an... | Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM) | [
{
"description": "Given IV",
"name": "Nab paclitaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ABI-007",
"Abraxane",
"Albumin-bound Paclitaxel",
"Protein-bound Paclitaxel"
],
"type": "Drug"
},
{
"description": "Given IV",
"n... | [
{
"design_group_description": "Patients receive nab-paclitaxel IV over 30-40 minutes, gemcitabine IV over 30-40 minutes, and cisplatin IV over 30-60 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT... | [
"Pancreatic Acinar Cell Carcinoma",
"Pancreatic Adenocarcinoma",
"Pancreatic Adenosquamous Carcinoma",
"Pancreatic Carcinoma",
"Pancreatic Ductal Adenocarcinoma",
"Pancreatic Squamous Cell Carcinoma",
"Stage IV Pancreatic Cancer AJCC v8"
] | [
"Alliance for Clinical Trials in Oncology"
] | [
"National Cancer Institute"
] | [
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
},
{
"name": "パクリタキセル(JAN)",
"lang": "JP"
}
],
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
... | null |
NCT00704379 | [
{
"id_field": "org_study_id",
"id_value": [
"R01NS055827"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01NS055827-01A2"
]
}
] | https://clinicaltrials.gov/study/NCT00704379 | Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury | The purpose of this study is to examine the efficacy of sertraline to prevent the onset of mood and anxiety disorders during the first six months after traumatic brain injury. | Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury | [
{
"description": "an inactive substance",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabil... | [
{
"design_group_description": "Placebo will be given in a double blind fashion via an equal number of tablets (identical to the sertraline tablets) administered once daily.",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3... | [
"Traumatic Brain Injury"
] | [
"Baylor College of Medicine"
] | [
"National Institute of Neurological Disorders & Stroke"
] | [
[
{
"name": "盐酸舍曲林",
"lang": "CN"
},
{
"name": "Sertraline Hydrochloride",
"lang": "EN"
},
{
"name": "セルトラリン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT01811940 | [
{
"id_field": "org_study_id",
"id_value": [
"#6698"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1U01DA033310-01A1"
]
},
{
"id_field": "acronym",
"id_value": [
"TACT2"
]
}
] | https://clinicaltrials.gov/study/NCT01811940 | Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence | The proposed protocol is a multi-site double-blind, placebo-controlled outpatient study of the safety and efficacy of Adderall-XR (MAS-ER) and topiramate in the treatment of cocaine dependence. 198 patients will be enrolled and 176 patients randomized in a 14-week trial. The proportion of participants achieving sustain... | Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence | [
{
"description": "MAS-ER 60mg/day",
"name": "Adderall-ER",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Adderall extended release (MAS-ER)"
],
"type": "Drug"
},
{
"description": "Topiramate 100 mg bid.",
"name": "Topiramate",
"normalized_type"... | [
{
"design_group_description": "Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morni... | [
"Cocaine Dependence"
] | [
"The New York State Psychiatric Institute"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "托吡酯",
"lang": "CN"
},
{
"name": "Topiramate",
"lang": "EN"
},
{
"name": "トピラマート",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "2e82289582028a2429de32e9238a899d",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TACT2"
}
] |
NCT02854800 | [
{
"id_field": "org_study_id",
"id_value": [
"WestVirginiaU"
]
},
{
"id_domain": "National Institute on Drug Abuse",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NOT-DA-16-013"
]
}
] | https://clinicaltrials.gov/study/NCT02854800 | Smoking Cessation & Opioid Dependence Treatment Integration | The primary purpose of this study was to examine the feasibility of integrating a smoking cessation intervention for cigarette smokers enrolled in an outpatient program for opioid dependence. The secondary purpose was to compare treatment effects as a function of phase in the outpatient program: 0-90 days (weekly atten... | Smoking Cessation & Opioid Dependence Treatment Integration: Does Timing Matter? | [
{
"description": "Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).",
"name": "varenicline",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Chantix... | [
{
"design_group_description": "Participants in this group attended an outpatient opioid clinic once per week. As part of the current study, they received 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill fo... | [
"Smoking Cessation",
"Opioid Related Disorders"
] | [
"West Virginia University"
] | [
"Pfizer Inc.",
"National Institute on Drug Abuse"
] | [
[
{
"name": "酒石酸伐尼克兰",
"lang": "CN"
},
{
"name": "Varenicline Tartrate",
"lang": "EN"
},
{
"name": "バレニクリン酒石酸塩",
"lang": "JP"
}
]
] | null |
NCT06126315 | [
{
"id_field": "org_study_id",
"id_value": [
"ALCALS"
]
},
{
"id_field": "acronym",
"id_value": [
"ALCALS"
]
}
] | https://clinicaltrials.gov/study/NCT06126315 | Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS | Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS). Primary study aim: The clinical objective consists of assessing the efficacy of ALCAR (two different dosages will be tested: 1.5g/day and 3g/day) on the... | A Randomized, Phase II/III Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS | [
{
"description": "Acetyl-l-carnitine",
"name": "Acetyl-l-carnitine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "placebo",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "2 pockets of ALCAR will be administered t.i.d for 48 weeks. Total daily dosage: 1.5 g",
"design_group_title": "alcar 1.5 g",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Amyotrophic Lateral Sclerosis"
] | [
"Istituto di Ricerche Farmacologiche Mario Negri"
] | [
"Cure For Mnd Foundation, Inc.",
"The University of Sydney"
] | [
[
{
"name": "乙酰左旋肉碱",
"lang": "CN"
},
{
"name": "Acetyl-L-carnitine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ALCALS"
}
] |
NCT06282588 | [
{
"id_field": "org_study_id",
"id_value": [
"CTO21042GZA"
]
},
{
"id_field": "acronym",
"id_value": [
"THUNDER"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CTO21042GZA"
]
}
] | https://clinicaltrials.gov/study/NCT06282588 | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers | This Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate cancer (PCa). The study contains both a randomized Phase 3 treatment intensification study, as w... | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/ 3 Trial | [
{
"description": "2x300 mg tablets twice daily, for up to 96 weeks",
"name": "Darolutamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BAY1841788",
"Nubeqa"
],
"type": "Drug"
},
{
"description": "2x300 mg tablets twice daily, for up to 96 wee... | [
{
"design_group_description": "Darolutamide for up to 96 weeks (24 months) and primary SOC RT",
"design_group_title": "Phase 2 Open Label",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_... | [
"Prostate Cancer"
] | [
"Cancer Research UK"
] | [
"Veracyte, Inc.",
"Bayer AG"
] | [
[
{
"name": "双羟萘酸曲普瑞林",
"lang": "CN"
},
{
"name": "Triptorelin Pamoate",
"lang": "EN"
}
],
[
{
"name": "醋酸地加瑞克",
"lang": "CN"
},
{
"name": "Degarelix Acetate",
"lang": "EN"
},
{
"name": "デガレリクス酢酸塩",
"lang": "JP"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "THUNDER"
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.